2017

Karl E. Peace Collection

University Libraries, Zach S. Henderson Library

Follow this and additional works at: https://digitalcommons.georgiasouthern.edu/finding-aids

Part of the History Commons, Medical Education Commons, and the Public Health Commons

Recommended Citation

https://digitalcommons.georgiasouthern.edu/finding-aids/100

This finding aid is brought to you for free and open access by Digital Commons@Georgia Southern. It has been accepted for inclusion in Finding Aids by an authorized administrator of Digital Commons@Georgia Southern. For more information, please contact digitalcommons@georgiasouthern.edu.
Karl E. Peace Collection

Collection Number:

Extent: 39 linear feet (39 boxes)

Abstract: The collection contains a large body of time starting relatively from his dissertation to the present. Books and papers published by Karl Peace and there rough drafts present in the collection that represent the bulk of Dr. Peace’s work. Many of his papers have drafts that have been reviewed by his colleagues. In addition to these drafts, a portion of the papers research material is included.

Language: English

Acquisition/Provenance Information: Collection donated by Karl E. Peace from his home and office in 2012

Access Requirements and Restrictions: None: collection is available to the public.

Copyright:

Citation Information: [item], folder number, box number, Karl E. Peace Collection, Zach S. Henderson Library Special Collections, Georgia Southern University

History: Dr. Peace started the company Biopharmaceutical Research Consultants Inc. in 1989, Journal of Biopharmaceutical Statistics and a symposium known as BASS or Biopharmaceutical Applied Statistical Symposium. His main concentration of study is in cancer research and Biostatistics, receiving numerous rewards for his research. Dr. Peace earned his undergraduate degree at Georgia Southern University, masters at Clemson University and his PhD from the Medical College of Virginia. Dr. Peace and Charles Hardy established the center for biostatistics at Georgia Southern University, with Dr. Peace returning to Statesboro when the University began to offer a masters degree in Biostatistics. Georgia Southern University houses the Jiann-Ping Hsu School of Public Health, named after Dr. Peace’s deceased wife. The School of Public Health is the first school of its kind in the University System of Georgia. Dr. Peace has published ten books and over one hundred articles. Dr. Peace has founded many scholarships for students at a wide scope of institutions. In addition to the scholarships, Dr. Peace has donated a large sum of money to other organizations and events, advancing students ability to obtain a degree.

Scope and Content: This collection is still undergoing processing. The collection contains only a small portion of pictures and artist renderings of Dr. Peace. The collection has been sorted into three main categories, manuscripts, teaching and research. A large collection of his books, articles and papers are contained in the
collection, many of which have proofs. There are a portion of transparencies for the
topics of Dr. Peace’s books, articles and papers. A majority of the transparencies are
past teaching tools that he used. As well as the transparencies there are slides that Dr.
Peace used for teaching as well.

**Subject Terms:** Georgia Southern University; Biostatistics; Cancer—Research.;
Statistics; Clinical Trials.; Genomics.; Biopharmaceuticals.; Clinical drug trials;
Bioavailability; Drug development.; Pharmaceuticals; Duodenal Ulcer.; Sucralfate;
Betaxolol; Verapamil; Proceedings of the National Academy of Sciences of the United
States of America; PNAS; Human Experimentation.; Oncology.; Efficacy of drugs; Meta-
analysis.; Markov Chains.; Bipolar Disorder.;

**Related Materials:**

**Contents Listing:**

1. Box 1: BASS Symposium
   1. BASS XI: Short Courses
      - Lecture 00:
      - Data Mining Introduction
      - Lecture 01:
      - All linear Statistical Methods are Special Cases of SVD
      - Lecture 02:
      - Data Mining of Large, Clinical Trials
      - Lecture 04:
      - Multiple Trees and Metabolomic Data
      - Lecture 06:
      - Multiple Blocks of Data rSVD and RP
      - Subgroup Analysis of Clinical Trials
      - Recursive Partitioning with a Multivariate Dependent
      - Lecture Notes
      - Design and Interim Monitoring of Flexible Clinical Trials
2. BASS XI: Tutorials
   - BASS XI: "A Brief for Breaking our Rules"
   - Breast Cancer Chemotherapy Treatment, Design, and Recent Advances
   - Determination of the Best Linear Unbiased Estimates (Blue) of
     Incomplete Data For The Analysis of Repeated Measurements In
     Clinical Trials
   - Endpoints in HIV/AIDS Clinical Trials
   - Lecture 04:
     Multiple Trees and Metabolomic Data
   - Lecture 06:
Multiple Blocks of Data rSVD and RP
- Subgroup Analysis of Clinical Trials
- Recursive Partitioning with a Multivariate Dependent
- Lecture Notes
- Design and Interim Monitoring of Flexible Clinical Trials
- Statistical Considerations in Biomarker Method Development & Validation

3. BASS XI: Tutorials continued
- Non-inferiority Trials -Hypotheses and Analyses
- Active Control Non-Inferiority Trial- The Hypothesis
- Multiple Primary Endpoints in Clinical Trials
- Optimal Adaptive vs. Optimal Group Sequential Designs
- Methods for Incorporating Flexibility in Clinical Trials
- Using Robust Parameter Design In Industrial Experiments
- Critical Path: An Overview
- Emerging Issues and Considerations in Clinical Trial Design
- Strategy for Drug Development
- Emerging Issues and Considerations in Manufacturing Quality Control and Assurance of Drug Products

4. BASS XIII: Short courses, Nov. 06
- Statistical Methods to Address Multiplicity:
  - Adaptive Designs and the One Study Paradigm versus the Two (or More) Studies Paradigm as the Primary Confirmatory Evidence for a New Medical Product Relative to a Control
- Statistical Methods to Address Multiplicity:
  - Statistical Considerations for the Conduct and Reporting of Interim Analyses
- Statistical Methods to Address Multiplicity:
  - Analyses for Sub-population Effects
- Statistical Methods to Address Multiplicity:
  - Discussion of Applications of SAS Macros for Multiplicity Adjustment
- Statistical Methods to Address Multiplicity:
  - Analysis of Covariance: Parametric and Nonparametric
- Statistical Methods to Address Multiplicity:
  - Methods for Multiple Group Comparisons Bass
- Statistical Methods to Address Multiplicity:
  - Overview for Issues and Methods for Multiple Endpoints
- Statistical Methods to Address Multiplicity:
○ Summary and Discussions for Points to Consider and Guidance for Multiplicity, Missing Data, and Adjustment for Baseline Covariates
  • Adaptive Design Methods in Clinical Trials
  • Statistical Methods to Address Multiplicity:
    ○ Discussion of Application of the MULTTEST Procedure in SAS
  • BASS XIII: Course Schedule

5. BASS XIII: Short courses continued Nov.06
  • Conditional Inference
  • Improving Statisticians’ Consulting Effectiveness
  • Using The Myers-Briggs Type Indicator
  • Improving One-On-One Communications Skills
  • Improving Group Communications
  • Chapter 1. The Babel Problem, The Partnering Solution

6. BASS XIII: Stat Symposium, Nov. 06
  • BASS XIII Thirteenth Annual Biopharmaceutical Applied Statistics Symposium
  • Simulation for Designing and Analyzing Clinical Trials
  • Comparison of Statistical Analysis Methods Using Modeling and Simulation for Modern Protocol Design
  • Design of Dose Response Clinical Trials
  • Resampling Based Multiple Testing
  • BASS XIII Insightful
  • Model Based Adaptive Dose Ranging Designs
  • Bioequivalence trials designed using adaptive methodologies

7. BASS XIII: Stat Symposium continued
  • A Comparison of Methods for Longitudinal Data with Missing Due to Truncation
  • Rescue Behavior and Imputation Strategies in Analgesic Studies
  • Multivariate Assays with Values Below the Lower Limit of Quantitation:
    ○ Parametric Estimation by Imputation and Maximum Likelihood
  • Variability in Gene Expression in Healthy Volunteers
  • Adaptive Design Methods in Clinical Trials
  • Considerations in Planning and Testing for Multiple Endpoints in Clinical Trials
  • Issues and Considerations in Composite Endpoints
  • Recent Results Concerning Multiplicities in Animal Carcinogenicity Studies
• Tree-structured gatekeeping procedures in clinical trials with multiple objectives
• BASS XIII Fellows
• BASS XIII letter from Karl E. Peace
• Our Keynote Speaker is Greg Campbell
• Letter to BASS Committee Members from Laura H. Gunn
• Adaptive Design Methods in Clinical Trials
• Housekeeping
• Program Abstracts Conference Sessions

8. BASS XIV: Stat Symposium, Nov. 07
• An Adaptive Dose Finding Design (DOSEFIND) Using a Nonlinear Dose Response Model
• Dose Response Analysis for Combination Products
• Parametric Bayesian Dose Response Modeling
• Concordance Analysis in Biopharmaceutical Industry
• Statistical Validation of Surrogate Markers
• An Introduction to Pathodynamics from the View of Liver Homeostasis Using the Ornstein-Uhlenbeck Process
• On the Analysis of Longitudinal Clinical Lab Data with Latent Mixture Models
• Some Thoughts on the Assessment of Pharmaceutical Safety Data
• Statistical Modeling and Graphical Analysis of Safety Data in Clinical Trials
• Absolute Risk: Clinical Applications and Controversies

9. BASS XIV: Stat Symposium continued Nov.07
• Adaptive Model-Based Designs in Clinical Drug Development
• A Nonlinear Model Based Method for Steady-state Assessment
• Moving Beyond QT…
• Strategies for Meta-Analyses of Randomized Clinical Trials Based on Individual Patient Data
• Statistical Issues in Predictive Toxicology
• Enriching and Mining Missing Data: Design and Analysis Issues
• Missing Data: The shape of things to come
• An Overview of Causal Inference and its Application in Clinical Trials
• Developing an Analytical Road Map for Incomplete Longitudinal Clinical Trial Data

10.BASS XIV: Stat methods for Biomarker Discovery, Nov. 07
• Statistical Learning From Data
• Prediction Methods
• Super Learning
• Super Learning in Prediction
• Informative Censoring Addressing Bias in Effect Estimates Due To Study Drop-out
• Assessing ETA Violations, and Selecting Attainable/Realistic Parameters
• Targeted MLE for Variable Importance and Causal Effect with Clinical Trial/Randomized and Observational Data
• Multiple Testing
  • Outline
  • Controlling FDR in Second Stage Analysis
  • Secondary Analysis
  • Resampling Based Multiple Testing
  • Targeted Maximum Likelihood Learning; Application to Realistic Variable Importance

11. BASS XIV: Stat Graph, Covariance Analysis, Nov. 07
  • Statistical Graphics
  • Statistical Problems to Document and to Avoid
  • How Should Change be Measured?
  • The Role of Covariable Adjustment in the Analysis of Clinical Trials
  • Bayesian Approaches to Design and Analysis of RCTs and Advantages over Frequentist Methods

12. BASS XV: Creating more effective graphs, Nov. 08
  • Creating More Effective Graphs
  • Creating More Effective Graphs with Applications to Clinical Trials and Electronic Medical Records:
    o Use of Advanced Computer Methods and Visualization Tools to Simplify the Analysis of Complex Clinical Drug Safety Data

13. BASS XV: Trial simulation, Nov. 08
  • Lecture 1: Mathematical Modeling And Trial Simulation In Medicine And Life Sciences
  • Lecture 2: Regulatory Aspects of Modeling And Simulation
  • Lecture 3: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach

  • Lecture 4: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
  • Lecture 5: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
  • Lecture 6: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
  • Lecture 7: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
• Lecture 8: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
• Lecture 9: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
• Lecture 10: Simulation For Designing And Analyzing Clinical Trials – A Statistical Approach
• Lecture 11: Pharmacokinetic & Pharmacodynamic Concepts
• Lecture 12: Pharmacology, Pharmacokinetics & Pharmacodynamics
• Lecture 13: Modeling In Biopharmaceutics, PK and PD
• Lecture 14: Modeling In Biopharmaceutics, PK and PD
• Lecture 15: Modeling In Biopharmaceutics, PK and PD

14. BASS XV: trial simulation continued
• Lecture 16: Modeling In Biopharmaceutics, PK and PD
• Lecture 17: Population Dynamics
• Lecture 18: Population Dynamics
• Lecture 18: Population Dynamics
• Lecture 19: Population Dynamics
• Lecture 20: Population Dynamics
• Lecture 21: Epidemics
• Lecture 22: Epidemics
• Lecture 23: Epidemics
• Lecture 24: Computational Neuroscience
• Lecture 25: Computational Neuroscience
• Lecture 26: Computational Neuroscience
• Lecture 27: Computational Neuroscience
• Lecture 28: Mathematical Modeling & Simulation
• Lecture 29: Mathematical Modeling & Simulation
• Lecture 30: Modeling Of the Human Heart
• Lecture 31: Modeling Of the Human Heart
• Lecture 32: Modeling Of the Human Heart

15. BASS XV: Cross-over Trials, Nov. 08
• The Design and Analysis of Cross-over Trials


17. BASS XVI: Stat Symposium Nov.09
• Controversial Issues in Clinical Trials
• Dose-finding in oncology clinical trials based on unit probability mass
• Implementing Response-Adaptive Randomization in Multi-Armed Survival Trials
• Evaluating Probability of Success in Oncology Clinical Trials
• Design and Analysis of a Cancer Prevention Trial: Plans and Results
• Comparing Conditional and Predictive Power to Assess Futility in a Phase III Program with Two Studies
• Comparing Conditional and Predictive Power to Assess Futility in a Phase III Program with Two Studies
• Setting Alpha Levels for Testing Key Secondary Endpoints in Trials with Interim Assessments when the Primary and Secondary Endpoints are Correlated
• Efficient Sampling of Inverse Correlation Matrices and its Applications in Bayesian Modeling of Gene Interaction in Early Phase Genomic Experiments
• The Mean Ain’t What It Used to Be
• Subgroup Data Analyses of Clinical Trials- Issues & Methods
• Analyses to Aid Dose Selection in Ph 2 Virology Clinical Trials Larry F. Leon

18. BASS XVI: Stat Symposium cont. Nov. 09
• Phase 2a “Power” Calculations: Comparisons with SOC
• Statistical Graphics for Exploratory Review and Reporting in Clinical Trials
• Statistical assessment and analyses of suicidality data in clinical trials: current challenges
• Retrospective Look: Logistics of Implementing a Suicidality Analysis
• Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
• Lifecycle Planning For Safety Evaluation In Support Of Benefit-Risk Activities
• On Methodologies Associated with Meta-analysis
• Targeted Maximum Likelihood Super Learning: Application to Causal Effects in Safety Analysis
• Letter from Laura H. Gunn to Bass Attendees
• Bass XVI Fellows
• Housekeeping
• Bass XVI Attendees

19. BASS XVI: Bayesian Methods, Nov. 09
• Recent Developments in Practical Bayesian Methods for Clinical Trials

20. BASS XVI: Fundamental Training, Nov. 09
• The Development and Execution of a Clinical Program
• Design of Dose Response Clinical Trials
• The Roles of the (Bio) Statistician in Clinical Trials
• Data Monitoring in Clinical Trials Using Prediction
• Data Monitoring Committees
• Planning and Reporting Your Analyses
• Noninferiority Trials
• Analysis of Efficacy
• Subgroup Analysis
• Benefit: Risk Assessment

21. BASS XVI: Bioequivalence & Statistics Nov. 09
• Bioequivalence and Statistics in Clinical Pharmacology

22. BASS XVII: Genomics, Nov. 10
• Introduction to Design of Genomic Clinical Trials
• Targeted (Enrichment) Design

23. BASS XVII: Tutorials, Nov. 10
• Multiplicity problems in clinical trials A regulatory perspective
• A Process View of Statistics for Clinical Trials: ANOVA, Product-Limit, and Adaptive Design
• Covariate-Adjusted Response-Adaptive Randomization Designs for Phase III Survival Trials
• Sample Size Re-estimation Using Adaptive Tests and Generalized Likelihood Ratio: A Comparative Study
• Failure-Time Mixture Models for Analyzing Time to Response
• Statistical Considerations in Multi-Regional Clinical Trials
• Enrollment and Event Projection in Oncology Trials
• Implementing the Continuous Reassessment Method (CRM) in a Phase I Oncology Trial
• Scaled Average Bioequivalence: An Approach to Resolve A Difficult Program
• Design of Non-inferiority Trials-Problems, Current Approaches and Applications of Inferiority Index
• Methodological Considerations in Comparative Effectiveness Research
• Estimation Issues for High Throughput Data
• Multiple Testing in a Partitioning framework
• Recent Development in Addressing Multiplicity Issues In Clinical Trials
• Decomposition of a Composite Endpoint for Assessing Treatment Benefits for its Components

24. BASS XVII: Koch & Stocks, Nov. 10
• Categorical Data Analysis Using SAS
• Quantal Bioassay Analysis
• The 2 x 2 Table
• The Final Session: Recent Topics in Categorical Data Analysis
- Biomarker Adaptive Threshold Design
- Development and Validation of Predictive Classifiers using High Dimensional Data
- Proportional Odds and Generalized Logits Models
- Weighted Least Squares for Mean Scores
- Sets of 2 x r and s x 2 Tables
- Poisson Regression
- Generalized Estimating Equations
  Box 2: Clinical Trials
- Folder 1: Clinical trials methodology (graduate course)
- Folder 2: Clinical trials methodology (graduate course) continued
- Folder 3: Clinical trials methodology
  a. Intro to methodology papers
  b. Analysis of Ratios and Decision Rules in Bioequivalence Studies
  c. Bioavailability and Bioequivalence of Pharmaceutical Formulations
  d. Design and Analysis of Pivotal Trials to Assess Efficacy of Drugs to Treat Panic
  e. Tagamet: Repairing Ulcers Without Surgery (excerpt)
  f. Analysis of Ratios and Decision Rules in Bioequivalence Studies
  g. Clinical Trials in the Prevention of NSAID Induced Gastric Ulceration
  h. Biostatistical Aspects of the Development of H2-Receptor Antagonist Drugs to Treat Duodenal Ulcers
  i. A Single Nocturnal Dose of Cimetidine in Active Duodenal Ulcer
  j. Cimetidine Single-Dose Active Duodenal Ulcer Trial
  k. Effects of Two Cimetidine Dosage Regimens on Serum Theophylline Levels
  l. Efficacy of a Single Nocturnal Dose of Cimetidine in Active Duodenal Ulcer
- Folder 4: Clinical trials methodology continued
  a. Biostatistical Aspects of the Development of Anti-Anginal Drugs: a Phase II Trial Incorporating an Equiradial Hexagonal Design with RSM
  b. The Importance of Numbers (of Patients) in Clinical Trials
  c. The Pooling of Data from Multicentre Clinical Trials
  d. Nonsequential Analysis of Time to Event Data
  e. Additional Examples of Time-To-Event Analyses
  f. Design Aspects of Cancer Clinical Trials
  g. FDA Requirements for Approval of New Drugs
h. Guidelines for the Clinical Evaluation of Antineoplastic Drugs, February 1981

- Folder 5: Clinical trials methodology (Grad course for MPH Biostat)
- Folder 6: Clinical trials methodology (Grad course for MPH Biostat)
  continued
  a. Statistical Principles for Clinical Trials
  b. Guideline for Good Clinical Practice
  c. Choice of Control Group and Related Issue in Clinical Trials
  d. Principles for Clinical Evaluation of New Antihypertensive Drugs
  e. FDA Organization Charts
  f. ICH Press Reports, 1997-2000
  g. User Fee Correspondence from the FDA, 1997
  h. Federal Register, 1999

- Folder 7: Clinical trials & Biostatistics
- Folder 8: Biostatistical aspects of clinical research programs
- Folder 9: Cancer clinical investigation review committee, Apr. 1978
  a. Bayesian Approach to Design of Clinical Trials
- Folder 10: Clinical trials talk at Duke, 03/26/2008
  a. Interesting Pharmaceutical Clinical Trial Applications
- Folder 11: Interval-censoring in Biopharmaceutical clinical trials, 07/14/2010
  a. Interval-Censoring in Biomedical and Biopharmaceutical Clinical Trials Presentation
  b. Interval-Censoring in Biomedical and Biopharmaceutical Clinical Trials Journal Article
- Folder 12: Education of clinical trial statisticians
  a. The Education of Clinical Trial Statisticians: Do we need to change with the time? Presentation
  b. DIA program, 1991
  c. Scott Evans Email, 2008
  d. Scott Evans Email, 2007
  e. Title page of the program for The Education of Clinical Trial Statisticians
  f. Some Comments on the Biopharmaceutical Section and Statistics, 1989
  g. The Future of the Education of Clinical Trial Statisticians: What Changes are Needed?
  h. XXIVth International Biometric Conference sheet
- Folder 13: Clinical trial protocol
- Folder 14: Workshop on clinical trials
a. Statistical Aspects of Clinical Drug Development

- Folder 15: Clinical trial workshop S.K.&F.
  a. Smith Kline and French In House Biostatistical Educational Program; A Two Day Session on the Clinical Trials Workshop and Seminar Series; Presentation 1983
- Folder 16: Workshop on clinical trials, Dec. 8-9, 1983
- Folder 17: Introduction to S.K.&F. clinical trials
  a. Papers and microfiche
- Folder 18: RAPS 1992
  a. Sample Size Considerations in Clinical Trials Premarket Approval, 1992
- Folder 19: Clinical trial transparencies
- Folder 20: Multicenter trials
- Numbers of patients in clinical trials
- S.K.&F. protocol (transparencies)
- Statistics & clinical trials
- Miscellaneous

Box 3: Transparencies

- Folder 1: Design Aspects of Cancer Clinical Trials
- Folder 2: Bioavailability & Bioequivalence
- Folder 3: Nonsequential Analysis of Time to Event Data
- Folder 4: Sequential Methods
- Folder 5: Sequential Methods continued
- Folder 6: Biostatistical Aspects of Clinical Drug Development
  o Includes microfiche
- Folder 7: Statistics Issues Course handouts
  o The Importance of Numbers (of Patients) in Cancer Clinical Trials
  o Additional Examples of Time-To-Event Analyses
- Folder 8: Statistical Issues Course continued (Photocopied Transparencies)
  o Active Control Equivalence Studies
  o Dosing in the Elderly
  o The Pooling of Data from Multi-Centre Clinical Trials
  o Design, Monitoring, and Analysis Issue Relative to Adverse Events
  o Summarization, Analysis, and Monitoring of Adverse Experiences, REFERENCES/Chapter 2
  o Two Treatment Crossover Designs References/Chapter 3
  o Active Control Equivalence Studies REFERENCES/Chapter 4
- Optimization in Clinical Trials and Combination Drug Development References/Chapter 5
- Meta-Analyses in Ulcer Disease
- An Evaluation of Triprolidine and Pseudoephedrine in the Treatment of Allergic Rhinitis
- Summarization, Analysis, and Monitoring of Adverse Experiences, REFERENCES/Chapter 2

- Folder 9: Graduate course in Biostatistics for Medical Personnel
  - Clinical Trials Methodology (name of Biostatistics course)
  - FDA Organization Charts
  - Canda Manual
  - FDA Organization Charts
- Folder 11: The Assessment of Drug Safety, 05/10/1988
- Folder 12: Monitoring Adverse Experiences in Clinical Drug Development

Box 4: Courses

- Folder 1: Courses: Institute for Professional Education, 1989-1990
- Folder 2: Courses: Drug Information Association, 1989
  - Correspondence
- Folder 3: Courses: Beaumont Hospital, 1989
  - Correspondence
- Folder 4: Courses: Statistical Aspects of Clinical Research Programs
- Folder 5: Short Course on Analysis of Cancer Clinical Trials
  - Nonsequential Analysis of Time to Event Data
  - Additional Examples of Time-To-Event Analyses
  - INCLUDES A Short Course on the Design of Cancer Clinical Trials
  - Design Aspects of Cancer Clinical Trials
  - Guidelines for the Clinical Evaluation of Antineoplastic Drugs
- Folder 6: Short Course on Analysis of Cancer Clinical Trials continued
  - Design Aspects of Cancer Clinical Trials
  - Nonsequential Analysis of Time to Event Data
  - The Importance of Numbers (of Patients) in Cancer Clinical Trials
- Folder 7: Guide for Biostatistical clinical trials methodology course
  - Course Overview
  - Biostatistical Aspects of the Development of Drugs to Treat Alzheimer's Disease based upon ‘Enrichment Designs’
- Binder of an Overview of the Regulation of Pharmaceuticals presentation I
• Binder of an Overview of the Process of Discovery, Basic Research, Clinical Development & Manufacturing in Pharmaceutical Development presentation II
• Binder of Biostatistical Aspects of Clinical Drug Development presentation III
• Binder of Bioavailability and Bioequivalence of Pharmaceutical Formulations presentation IV-a
• Binder of Analysis of Ratios and Decision Rules in Bioequivalence Studies presentation IV-b
• Binder of The Design and Analysis of Pivotal Clinical Trials to Assess the Efficacy of Drugs to Treat Panic Disorder presentation V
• Binder of Clinical Trials in the Prevention of NSAID Induced Gastric Ulceration presentation VI
• Binder of Biostatistical Aspects of the Development of H-2 Receptor Antagonist Drugs in the Treatment of Duodenal Ulcer presentation VII
• Binder of Biostatistical Aspects of the Development of Anti-Anginal Drugs: a Phase II Clinical Trial Incorporating an Equiradial Hexagonal Design with Response Surface Methodology presentation VIII
• Binder of The Importance of Numbers (of Patients) in Cancer Clinical Trials presentation IX
• Binder of Biostatistical Aspects of the Design of Cancer Clinical Trials presentation X
• Binder of Biostatistical Aspects of the Analysis and Interpretation of Cancer Clinical Trials presentation XI
• Binder of Monitoring Adverse Experiences in Clinical Drug Development presentation XII
• Binder of The Pooling of Data from Multicentre Clinical Trials presentation XIII
• Binder of Interim Analyses: p-Value and Power Computations in Multiple Look Trials presentation XIV
• Binder of Biostatistical Aspects of Development of Drugs to Treat Alzheimer’s Disease Based Upon Enrichment Designs presentation XV
• Folder 8; J &J Course, 1990 (Johnson & Johnson)
• Folder 9; Lectures (Oncology studies)
  • Statistical Input into the Design, Analysis and Interpretation of Oncology Studies
  • Nonsequential Analysis of Time to Event Data
  • Additional Examples of Time-To-Event Analyses
  • Non-sequential Analysis of Time To Event Data
  • Survival Analysis Articles x5
  • Analysis of Survival Data Articles x4
  • Multivariate Survival Analysis Articles and Articles on Competing Risks
• Folder 10; Lectures (Oncology studies) continued
  ○ Design Aspects of Cancer Clinical Trials
  ○ Connection Between the Mantel-Haenszel and Cox Procedures for the Two Sample Case, 1979
  ○ A Parametric Model with Covariates or Cox’s Procedure? 1984
• Folder 11; Clinical trials & Biostatistics lecture
  ○ Thank You Card
  ○ Clinical Trials and Biostatistics presentation
  ○ Real Problems Call for Statistical Solutions presentation
• Folder 12; Biostatistical aspects of development of drugs lecture
  ○ Biostatistical Aspects of Development of Drugs to Treat Alzheimer’s Disease Based Upon Enrichment Designs
• Folder 13; Prevention of NSAID lecture
  ○ Clinical Trials in the Prevention of NSAID Induced Gastric Ulceration
• Folder 14; Interesting Applications from Three Decades of Biostatistic Consulting lecture

Box 5: Case Studies

• Folder 1: Matched pair design in controlling confounding factors in spontaneous duodenal ulcer relapse, 1987
• Folder 2: Study design for the assessment of misoprostol in the treatment & prophylaxis of NSAID induced peptic ulcer, 1987
• Folder 3: A blind endoscopic comparative study of misoprostol vs. sucralfate & placebo in the prevention of aspirin-induced gastric & duodenal ulceration, 1987
• Folder 4: A blind endoscopic comparative study of misoprostol vs. sucralfate & placebo in the prevention of aspirin-induced gastric & duodenal ulceration (continued), 1987
• Folder 5: Duodenal ulcer- what comes after healing? 1987
• Folder 6: Prevention of gastric ulceration upon reinstituting NSAID therapy in Osteo-Arthritic patients, 1987-1988
  ○ Meta-analysis of Duodenal Ulcer Relapses Using Actual Patient Data: A Comparison of the Effect of Acute Treatment with Cimetidine, Misoprostol and Placebo
• Folder 7: NEJM manuscript, 1985-1986
  ○ Acid Suppression – How Much and When for Acute Duodenal Ulcer Healing?
  ○ Nocturnal Cimetidine Therapy to Treat Duodenal Ulcers; a Dose Response Study
- One Article by John Romankiewicz
  - Effectiveness of Cimetidine in Doses of 400 mg, 800 mg and 1600 mg Given at Bedtime for the Acute Treatment of Duodenal Ulcers
- Folder 8: Maxzide clinical manuscript 11/1987
  - Comparative Bioavailability of Two Pharmaceutical Formulations Containing Hydrochlorothiazide and Triamterene
  - Influence of Tablet Dissolution on Furosemide Bioavailability: A Bioequivalence Study by McNamara, Foster, Digenis, Patel, Craig, Welling, Rapaka, Prasad, and Shah
- Folder 9: A double-blind crossover comparison of equal daily doses, 1987
  - Two Abstracts for the American College of Cardiology
  - Comparison of Equivalent Oral Doses of Verapamil and Diltiazem in Patients with Mild to Moderate Hypertension
  - A Double Blind Crossover Comparison of Equivalent Doses of Oral Verapamil and Diltiazem in Patients with Mild to Moderate Hypertension
  - Comparison of Steady State Plasma Profiles of Betaxalol and Atenolol
  - Betaxalo/Atenolol Studies
  - Preliminary Studies
  - The Steady State Plasma Profile of Betaxalol as Compared to Atenolol
- Folder 11: Bioequivalency of controlled release & sustained release formulations of verapamil HCL following multiple dosing in normal healthy male volunteers, 1987
  - Comparative Steady State Bioavailability of Conventional and Controlled-Release Formulations of Albuterol by Powell, Weisberger, Dowdy, Gural, Symchowicz, and Patrick (1987)
- Folder 12: Estimation of survival parameters
- Folder 13: Some results in the estimation of survival parameters
- Folder 14: A brief review of correlation, 10/1976
- Folder 15: Statistical report of Searle protocol, 1988
  - Abstract to the American College of Cardiology: Variability of Left Ventricular Mass Measurements by Ultrafast Computed Tomography
  - Abstract to the American College of Cardiology: Measurement of Myocardial Blood Flow After Transdermal Nitroglycerin by Ultrafast Computed Tomography
- Folder 16: Sequential analysis book visuals, 04/1986
  - P-Value and Power Computation in Multiple Look Trials transparency
  - Mathematical Statistics by Thomas Ferguson
  - Sequential Tests of Hypotheses for the Reliability of a 2-Parameter Weibull System by Harter, Moore, and Wiegand
- Notes
- Correspondence
- Effect of Antilymphocyte-Globulin Potency on Survival of Cadaver Renal Transplants, 1977
- Performing a Survival Analysis Instead of an Endpoint Analysis
- The Design of a Sequential Clinical Trial for the Comparison of Two Lung Cancer Treatments by Jones, Newman, and Whitehead (1982)
- Sequential Analysis of Survival Data in Clinical Trials by Gordon Lan (1984; handwritten)
- Discrete Sequential Boundaries for Clinical Trials by Lan and DeMets (1983)
- More Flexible Sequential and Non-Sequential Designs in Long-Term Clinical Trials by Lan, DeMets, and Halperin
- Temple University program for Gordon Lan’s Sequential Analysis of Survival Data in Clinical Trials
- Exact Confidence Intervals Following a Group Sequential Test by Tsiatis, Rosner, and Mehta (1983)

**Folder 17: Sequential analysis book visuals continued**
- Notes
  - A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples by Edmund Gehan (1965)
  - ‘Lecture 6’ Notes
  - Evaluation of Survival Data and Two New Rank Order Statistics Arising in its Consideration by Nathaniel Mantel (1966)
  - Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data by Mantel and Byar (1974)
  - The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy by Freireich, Gehan, Frei, Schroeder, Wolman, et al.
- Notes

**Folder 18: Exposure analysis of Dichotomous response measures in long-term studies, 1993**

**Folder 19: Summary of BRCI analyses of ADAS-Cog & CGIC from protocols CI-970-01, 04, and 06; 11/1992**

**Folder 20: Ulcer papers, 80’s & one 2011**
- Meta-Analyses in Ulcer Disease
  - Effects of Two Cimetidine Dosage Regimens on Serum Theophylline Levels by Seaman, Randolph, Peace, Frank, Dickson, Puterman, and Young (1985)
- The Treatment of Gastric Ulcer with Antisecretory Drugs: Relationship of Pharmacological Effect to Healing Rates by Howden, Jones, Peace, Burget, and Hunt (1988)
- Case Study in Optimal Dosing in Duodenal Ulcer
- Info on the 'Peptic Ulcer Disease' book
- Early Termination of Two Trials of Misoprostol in the Prevention of NSAID-Induced Gastric Ulceration (1992)
- Efficacy of a Single Nocturnal Dose of Cimetidine in Active Duodenal Ulcer by Valenzuela, Dickson, Dixon, Peace, Putterman, and Young (1985)
- A Single Nocturnal Dose of Cimetidine in Active Duodenal Ulcer by Peace, Dickson, Dixon, Putterman, and Young (1985)
- Cimetidine Single Dose Active Duodenal Ulcer Trial by Dickson, Dixon, Peace, Putterman, and Young (1985)
- Determining the Optimal Dosage Regimen for H2-Receptor Antagonist Therapy – a dose validation approach by Young, Frank, Dickson, Peace, Braverman, and Mounce (1989)
- Slideshow presentation on Cimetidine and Duodenal Ulcers
- Notes
  - Folder 21: A brief review of correlation, 1/77
  - Folder 22: Time to event data, 1988-2006
  - Folder 23: Prediction probabilities in stability studies, 11/83
  - Folder 24: Monitoring & analysis issues relative to adverse events, 1985-1987
  - Folder 25: Appendix 9. Methodology for the computation of partial areas under the Nar time curve
  - Folder 26: Size & power assessments of tests of hypotheses on survival parameters, 1978-1980
  - Folder 27: Second revision of size & power assessments of tests of hypotheses on survival parameters, 1977-1978
  - Folder 28: Efficiency assessments of tests of hypotheses on survival parameters, 1976-1977

Box 6: Manuscripts

- Folder 1: Size & power assessments of tests of hypotheses on survival parameters
- Folder 2: Exposure analysis of Dichotomous data
  - Exposure Analysis of Dichotomous Data draft and transparencies
  - On the Analysis of a Combination of Two Primary Efficacy Measures
Folder 3: Estimating the probability of the superiority of one treatment to another, 8/9/85
Folder 4: A brief review of correlation, 11/19/76
  • Includes transparencies
Folder 5: Connection between the Mantel-Haenszel & Cox procedures for the two sample case, 12/17/79
Folder 6: Some results in the estimation of survival parameters, 4/30/76
Folder 7: Proceedings of the National Academy of Sciences (PNAS)
  • miscellaneous, 1992
    • Results and Validation of a Population Pharmacodynamic Model for Cognitive Effects in Alzheimer Patients Treated with Tacrine by Holford and Peace (1992)
    • A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer’s Disease by Davis, Thal, Gamzu, Davis, Woolson, Gracon, et al.
    • Controlled Trial of Tacrine by Farlow et al
Folder 8: Proceedings of the National Academy of Sciences (PNAS)
  • miscellaneous continued, 1992
    • A Controlled Trial of Tacrine in Alzheimer’s Disease by Farlow, Gracon, Hershey, Lewis, Sadowsky, and Dolan-Ureno (1992)
    • Results and Validation of a Population Pharmacodynamic Model for Cognitive Effects in Alzheimer Patients Treated with Tacrine by Holford and Peace (1992)
Folder 9: Final Proceedings of the National Academy of Sciences (PNAS)
  • manuscripts, 1992
    • Methodological Aspects of a Population Pharmacodynamic Model for Cognitive Effects in Alzheimer Patients Treated with Tacrine by Holford and Peace
      • Draft of this article too
    • Results and Validation of a Population Pharmacodynamic Model for Cognitive Effects in Alzheimer Patients Treated with Tacrine by Holford and Peace
      • Draft of this article too
- Folder 10: Proceedings of the National Academy of Sciences (PNAS) manuscripts: reviewer/revisions, 1992
  - Tacrine in Alzheimer’s Disease: A Population Pharmacodynamic Model for Cognitive Effects parts I and II
    - Includes a set of drafts
- Folder 11: Proceedings of the National Academy of Sciences (PNAS) manuscripts: reviewer/revisions continued, 6/29/92
  - Tacrine in Alzheimer’s Disease: A Population Pharmacodynamic Model for Cognitive Effects parts I and II Drafts
- Folder 12: Determining type I & type II errors in multiple trials, 1980
  - Size of the Type I Error at which to Conduct an Interim Analysis in Order that the Results of the Interim and Final Analyses are Significant, 1980
- Folder 13: Letters to the editor
- Folder 14: Letters to the editor: NEJM (New England Journal of Medicine), 1984
- Folder 15: Letters to the editor: Lancet, 11/10/84
- Folder 16: Letters to the editor: journal of chronic diseases, 1987
- Folder 17: JBS subgroup paper, 2009-2010
  - Analysis of Subgroup Data of Clinical Trials by Tsai and Peace
- Folder 18: Duodenal ulcers paper, 1/2010
  - Clinically Optimal Dosing in the Treatment of Duodenal Ulcers: A Case Study of a Phase III SNDA Clinical Program
- Folder 19: DIA sample size, 11/19/91
  - Sample Size Considerations in Clinical Trials Premarket Approval
- Folder 20: Manuscripts with Kao-Tai Tsai, 2005
  - Multivariate Dose Response Test by Kao-Tai Tsai and Karl Peace
- Folder 21: Multivariate dose response JMS; Peace & Tsai, 2007
  - Multivariate Dose Response Test by Kao-Tai Tsai and Karl Peace
    - Includes Drafts and a powerpoint
  - Correspondence
  - Nonparametric Two-Sample Comparisons of Changes on Ordinal Responses by Bajorski and Petkau (1999)
- Folder 22: A brief introduction to survival curve estimation, 10/31/75
- Folder 23: Some results in the estimation of survival parameters, 4/30/76
- Folder 24: Estimation & tests of hypotheses on survival parameters, 5/17/79
- Folder 25: A brief review of correlation
- Folder 27: Bivariate plot paper JBS, 2008-2009
  - Bivariate or Composite Plots of Endpoints by Peace and Tsai
  - Bivariate or Composite Plots of Primary Endpoints by Peace and Tsai
- Multivariate Dose Response Test by Tsai and Peace
  - Various versions
- Article comments from reviewers
- Folder 29: The use of response surface methodology in the development of antianginal drugs (handout), 5/29/86
- Folder 30: Lopid manuscripts: HHS I: exposure analysis, 11/23/91
  - Statistical Analysis Methods for Providing Inferences between Primary Response Measures and Exposure to Study Medication in the Helsinki Heart Study: Double Blind and Open Label Periods by Peace and Haber (1991)
  - Exposure Analysis of Dichotomous Response Measures in Long Term Studies, 1992
  - Statistical Analysis Methods for Providing Inferences Between Primary Response Measures and Exposure to Study Medication in Long Term Studies
  - Drafts, Revisions, and Reviews
  - Compliance as an Explanatory Variable in Clinical Trials by Efron and Feldman (1991)
- Folder 32: Lopid manuscripts: Zweig & Urquhart, 92-93
  - Correspondences
  - Xerox Telecopied Compliance as an Explanatory Variable in Clinical Trials by Efron and Feldman (1991)
  - Medication Compliance and Serum Lipid Changes in the Helsinki Heart Study by Maenpaa, Heinonen, and Manninen (1991)
- Folder 33: Life time learning publications, 1/10/83
- Folder 34: Miscellaneous papers from Biopharmaceutical research consultants, INC.
  - Biostatistical Aspects of the Development of Anti-anginal Drugs: a Phase II Trial Incorporating an Equiradial Hexagonal Design with RSM notes
  - Design and Analysis of Pivotal Trials to Assess Efficacy of Drugs to Treat Panic notes
- Biostatistical Aspects of the Development of Drugs to Treat Alzheimer’s Disease based upon ‘Enrichment Designs’
- Monitoring Adverse Experiences in Clinical Drug Development
- Folder 35: Miscellaneous papers from Biopharmaceutical research consultants, INC. continued
  - Monitoring Adverse Experiences in Clinical Drug Development
  - Bioavailability and Bioequivalence of Pharmaceutical Formulations
  - Analysis of Ratios and Decision Rules in Bioequivalence Studies
  - Biostatistical Aspects of the Development of H2-Receptor Antagonist Drugs to Treat Duodenal Ulcers
- Folder 36: SJS (Steven Johnson Syndrom) research, 2004
  - (Re)Assessing the Co-Administration of Steroids and Antibiotics in the Management of Patients with Metastatic Brain Cancer research proposal
  - Correspondence
  - Notes
  - Intention-to-Treat Analysis and Accounting for Missing Data in Orthopaedic Randomized Clinical Trials by Herman, Botser, Tenenbaum, and Chechick (2010)
- Folder 37: Drug information journal: articles, 87 & 93
  - Design, Monitoring, and Analysis Issues Relative to Adverse Events, 1987
  - Discussion for Interim Analysis and Sample Size Reestimation, 1993
- Folder 38: Analysis of efficacy data on IBS patients, 6/9/81

2. Box 7: Manuscripts

- Folder 1: To The Editor: Giles Robertson, 1975
  - Math notes
  - The Hypocalcemia of Acute Pancreatitis
  - Giles Robertson
  - To the Editor
- Folder 2: Chapter 3: Section 1-3 deleted
  - 3.1.1.1.2 : The Weibull Density
- Folder 3: Note concerning Fishers Method for Combining P-values
  - Notes
• Folder 4: Letter about Journals 10/1/82
  ○ Notes
• Folder 5: Analysis & interpretation of log transformed DATA 8/15/85
  ○ On The Analysis and Interpretation of log Transformed DATA
  ○ Background
  ○ Theory and Methods
  ○ Simulation
  ○ Results
  ○ Discussion
  ○ Strategy
• Folder 6: Hale’s Problem 2/05/79
  ○ Math Notes
  ○ The Teacher’s Corner
  ○ Designs for Estimating Variance Components
  ○ Introduction
  ○ Variances of Estimated Variance Components for a Three Stage Nested Classification
  ○ Optimal Designs for Estimating Parameters for a Three Stage Nested Classification
  ○ Some Aspects of the Simultaneous Estimation of Variance Components For a Three Stage Nested Classification
• Folder 7: Goodness of Fit Test for Survival Models 10/3/79
  ○ Goodness of Fit Test For Failure Time Models utilizing covariates
  ○ Goodness of Fit Test For Model
  ○ Comparing Observed Life Table Data with a Known Survival Curve in the Presence of Random Censorship
  ○ Math notes
  ○ Letter from Karl E. Peace to Dr. Carol Redmond
• Folder 9: Endpoint Analysis of DATA from trial of cyclical Disease
  ○ Endpoint Analysis of Data
  ○ Weighting Proportions
  ○ Math Notes
• Folder 10: Analysis of F &Z data, Freireich data & T.P. data, 2/3/76
• Folder 11: Analysis of F &Z data, Freireich data & T.P. data continued, 2/3/76
• Folder 12: Yvonne efficiency article
  ○ Efficiency Assessments of Tests of Hypotheses on Survival Parameters
• Folder 13: RPB
• Folder 14: Dose response problem, 10/15/91
  ○ Medical College of Virginia
• Folder 15: Iterative solutions of F &Z normal equations, 12/65
- Program For The Iterative Solution Of The Normal Equations of Feigl and Zelen
- Estimation of Exponential Survival Probabilities with Concomitant Information: Feigl and Zelen
- Folder 16: Survival curve anthology idea
  - An Anthology of Survival Curve Estimation
  - Chapter 3: The Actuarial Method
- Folder 17: Contrasting linear additive model with YIJ
- Folder 18: Parameter estimation LDIO, LDSO, etc, 1/9/85

- Pinhole Tester (Densok)
- Folder 19: Nature of the Difference Between The Mantel-Haenszel
- Folder 20: Parameter Estimating LD10,LD50, ETC 1/9/85
  - Northwest Orient
- Folder 21: Europa distribution related book
- Folder 22: Guide to decision making involving human experimentation (C.K. Himmelsback), 12/30/76
  - Letter to Chif
  - Guide to Decision Making in Human Experimentation
- Folder 23: Consulting project: Giles, 9/10/75
  - The Hypocalcemia of Acute Pancreatitis
  - Letter to the Editor
  - Letter to Giles from Karl
  - Final Letter to the Editor From Karl
- Folder 24: Study proposals for generics, 1982
  - Study Proposites For Generies Existing Indications
  - Clinical Research Protocol
- Folder 25: Design, Analysis & Interpretation of Oncology Trials 1/9/84

1. Note concerning Fishers method for combining P-values
2. Letter about journals, 10/1/82
3. Analysis & interpretation of log transformed data, 8/15/85
4. Hale’s problem, 2/05/79
5. Goodness of fit test for survival models, 10/3/79
6. GCM analysis of Quantal data, 11/8/85
7. Endpoint analysis of data from trial of cyclical disease
10. Yvonne efficiency article
11. RPB
12. Dose response problem, 10/15/91
13. Iterative solutions of F &Z normal equations, 12/65
14. Survival curve anthology idea
15. Contrasting linear additive model with YIJ
16. Pinhole testing problem, 6/6/79
17. On the nature of the difference between the Mantle-Haenszel, PETO & PETO tests
18. Parameter estimation LDIO, LDSO, etc, 1/9/85
19. Europa distribution related book
20. Guide to decision making involving human experimentation (C.K. Himmelsback), 12/30/76
21. Consulting project: Giles, 9/10/75
22. Study proposals for generics, 1982
23. Design, Analysis & Interpretation of Oncology trials, 1/9/84
24. Mathematical Physiology (Finite Markov chains & stochastic processes with applications), 1976
25. A brief introduction to survival curve estimation, 10/31/1975
26. Marginal likelihoods based on Cox's regression & life model, 1972
27. Marginal likelihoods based on Cox's regression & life model continued, 1972

3. Box 8: Manuscripts
   1. One-sided or Two-sided? 8/16/1988
   2. One-sided or Two-sided? Continued, 8/16/1988
   3. Some thoughts on One-tailed tests (letter to the editor), 1988
   4. Technometrics letter to the editor, 10/1/1980
   5. The treatment of gastric ulcer with antisecretory drugs, 10/86
   6. What hypothesis is being addressed in the analysis of change scores? 6/10/80
   7. A characterization of the effect of varying sample sizes, subject to a fixed total, on detecting a difference in two means, 1/7/80
   8. Tests of hypothesis in two by two tables, 1980
   9. Connection between the Mantel-Haenszel & Cox procedures for the two sample case, 3/14/80
10. The Statistician Article: A two-treatment, two-period, crossover design permitting assessment of direct & carry-over effects, 8/23/83
11. P-value & power computations in multiple look trials, 1987
12. P-value & power computations in multiple look trials, 4/3/86
13. P-value & power computations in multiple look trials continued, 4/3/86
14. Charts P-value & power computations, 4/3/86
15. Design, analysis & interpretation of Oncology trials, 12/14/84
19. Statistics handouts by K.E.P.
20. Statistics handouts by K.E.P. continued
21. PSA papers (Panic trials 06, Survival analysis instead of an end point analysis for antibiotic data 06, Statistical analysis methods for providing inferences between primary response measures 06)
22. ASA articles, 1989 & 2008

4. Box 9: MISC
   1. Berkeley Wellness Letters
   2. Jiann-Ping Hsu College of Public Health

5. Box 10: MISC
   (loose items)
6. Car calendars- pictures from the private collection of Dr. Karl E. Peace
   1. (white binder)
      - Biopharmaceutical Research Consultants, Inc. Standard Operating Procedures
   2. (black binder)
      - Health Systems Plan 1979-1980
      (items not in folder)
-Speaker and Brochure Information- Optimizing Dose and Exposure-Response Studies to Reduce Drug Development Time and Expense
   - The Summer Meeting in Eugene
3. 1986 Munice Meetings 5/29/86 and The 1986 Midwest Biopharmaceutical Workshop
4. “Issues Concerning the Dose Comparison Trail” PMA 1983 Annual Meeting
5. APHA Meeting (7/25-27, 2010)
6. APHA Meeting – December 11, 2010
7. Inter-Sectional Council (ISC) Agenda –APHA (transparent folder)
8. APHA- Philly 11/10-11/12 2009
   (loose item)
   - The History of the Biopharmaceutical Section of the American Statistical Association (ASA), 1966-1988
9. Column for PSA Newsletter
10. PSA Column 1: Q or A? Importance of the Research Questions relative to Analyses
11. Letter to the Editor
   - Is it better to have many small trials or few large trials?
- Observations
- Some Thoughts on Confirmatory Evidence (CE) to Support a Single Clinical Trial as a Basis for Drug Approval
  - Clinical Development Program
  - On the Need for Placebo in Combination Drug Development
  - Combination Drugs
  - Placebo is needed to Establish Efficacy in Combination Drug Development
- Response
  - letter from Karl E. Peace to Dr. Alvan R. Reinstein Jan 22, 1990
  - letter to the Editor
  - letter from Karl E. Peace to Dr. Alvan R. Reinstein Jan 17, 1990
  - letter from Alvan R. Reinstein and Walter O. Spitzer to Karl E. Peace
    - handwritten pages – stapled
    - The Impact of Investigator Heterogeneity in clinical Trials on Detecting Treatment Differences
  - Some Comments on the Biopharmaceutical Section and Statistics
12. PSA Column 2: Validity of Statistical Inferences from Medical Experiments (PSA Newsletter)
13. PSA Column 3: “Fixed Combination…”
14. PSA Column 4: “Bio statistical Aspects of NSAID and Gastric Ulcers”
15. Manuscripts for PAS
  - email correspondence between Joselito C. Magadia and Karl E. Peace
  - mathematical update and clarification
  - email correspondence between Jose Ramon G. Albert and Karl Peace
16. Talk to PSA
  - receipts including hotel bill
  - email correspondence between William I. Griffis and Karl E. Peace
  - email correspondence between Dalsay Malagalig and Karl E. Peace
  - travel agent invoice
  - email correspondence between Robert Vogel and Karl E. Peace
  - email correspondence between Jose Ramon G. Albert and Dalisay Malagalig
17. Combination GSU and UP Los Banos
  - email correspondence between Nancy Shumaker and Karl E. Peace
  - email correspondence between Dr. Carter and Karl E. Peace
  - background
18. Related to PSA Newsletter
19. PS column: statistics in medical science
20. PS Column: Statistics in medical science
21. ASA Summer Meeting – 1994
22. Comparative Advertising Claim Poop
   (loose items)
23. Efficacy
24. Analysis of Survival Data Course (browned accordion folder)
25. Unlabeled
- Assessment of Drug Safety
- PMA Education and Research Institute (PERI) Third Annual Training Course for New Clinical Statisticians March 11 -13, 1990
- The FDA and the IND/NDA Statistical Review Process
- Bioavailability/ Bioequivalence Trials Design and Evaluation
- Protocol Development – A Statistician’s Point of View
- Planning of Clinical Studies
- Acceleration of the Drug Approval Process
- Investigational New Drug, Antibiotic, and Biological Drug Product Regulations: Procedures for Drugs Intended to Treat Life-Threatening and Severely Debilitating Illnesses
- Efficacy Analysis with Missing Data
- Interim Analysis
- Multicenter Studies
- General Linear Models Procedure

26. Statistical Services Seminar
   (loose items)
   - Pharmacometrics Impact on FDA Decisions and Recommendations: Past, Present, and Future

27. Unlabeled
   - letter from Drug Information Association
   - two sheets of slides – statistical Considerations in the design and Analysis of LOPID-MR Placebo-Controlled Study
   (loose items)
   - regulatory affairs
   - Clinical Studies: how to Successfully Resolve Clinical Problems to Achieve FDA Approval

28. Graybill Conference VII

7. Box 11: Slides
   1. Teaching
   2. MIS

8. Box 12: MISC
   1. Stats
      - Statistical Analysis Methods for Providing Inferences between Primary Response Measures and Exposure to Study Medication
      - A Survival Analysis Instead of an Endpoint Analysis for Antibiotic Data
      - Statistical Computing and Graphics – Word from Computing Section Chair
      - Statistical Methods for a Three-Period Crossover Design in Which High Dose Cannot Be Used First
      - Statistical Input into the Design, Analysis and Interpretation of Clinical Trials
- Assessing the Validity of Statistical Inferences in Public Health Research: an Evidence-Based, 'Best Practices' Approach
- Statistical Methods for a Three-Period Crossover Design in Which High Dose Cannot Be Used First
- Statistics in Medical Science-Importance of Research Question Relative to Analyses

2. Stats (cont’d)
- Some Comments on the Biopharmaceutical Section and Statistics
- Some Thoughts on the Development of Combination Drugs
- The history of the Biopharmaceutical Section of the American Statistical Association (ASA), 1966-1988
- Introduction of the Bass XVIII Keynote Speaker Dr. Marvin Zelen
- Making Informed Consent More Ethical
- A Call to Action
- Safety of Drugs, indeed, a Lifecycle Exercise
- An Evaluation of Triprolidine and Pseudoephedrine in the Treatment of Allergic Rhinitis
- Discussion for Interim Analysis and Sample Size Reestimation
- Statistical Tests for Indirectly Standardized Rates
- Appendix 1 Statistical Test
  (Loose items)
- Resampling Stats- Probability and Statistics a Radically Different Way
  User Guide IBM Version 3.0 (w/2 floppy disks)
- Journal of Biopharmaceutical Statistics
- Purpose of Experimentation or Observation (transparent slides)
- Resampling Stats – Probability and Statistics a Radically Different Way
  IBM Version 2.0
  (in blue folder)
- Biotechnology and the Biostatistician
- Keynote Address, Preliminary Comments: by Karl Peace, BASS Chair,
  GCC Distinguished Cancer Scholar, Senior Research Scientist, JPHCPH,
  GSU.
- Summary of Linear Models Analyses of ADAS-COG and CGIC Scores
  from Three Placebo Controlled, Enrichment Studies of Tacrine
- Discussion: Linear Models and Population PK/PD Models
- Statistical Issues in the Pharmaceutical Industry: Design, Analysis and
  Interpretation Issues in Clinical Trails
- The Effect of Tacrine on Alzheimer’s Disease
- Analysis of Menstrual Data from Contraceptive Trials
- Comparing Treatment Groups on the Basis of Slopes, Areas-Under-The-Curve, and Other Summary Measures
- Maximum Likelihood Assessment of Clinical Trials based on an Ordered Categorical Response Variable
- Reducing the Cost of Clinical Trails
- Statistical Issues in the Pharmaceutical Industry: Design, analysis and Interpretation Issues in Clinical Trials

3. Wyeth Ayerst
   - Hotel receipt
   - Wyeth-Ayerst Biostatistical Seminar
   - Handwritten note on Biopharmaceutical Research Consultants Inc. letterhead
   - Letter from Richard Entsua, Ph.D to Karl Peace about Wyeth-Ayerst seminar
   - Some Statistical Issues in Pharmaceutical Applications
   - Memo to Dr. Richard Entsua from Karl Peace – Abstract of Presentation
   - Handwritten note
   - Note from Dr. Richard Entsua from Karl Peace

4. Barnett Educational Services: Drug Development
   - Applying FDA’s Critical Path Initiative to Oncology Drug Development
   - Drug Development: Changing the Paradigm outline
   - Speaker and Brochure Information- Drug Development: the Changing Paradigm
   - Karl E. Peace, Ph. D. Biographical Sketch
   - Sample Size Considerations in Clinical Trials Pre-Market Approved.

5. Three-Period Crossover

6. Placebo v. Tacrine
   - Study 4
   - Study 5
   - Study 6
   - Comparisons of Improvement vs. No Improvement for ADAS-COG, CGIC, and combined
   - Summary of Dose Response Analyses ADAS-COG at End of DB Treatment
   - Summary of Life Table Analyses of Time to First Clinical Response
   - Summary of Linear Model Analyses of ADAS-COG and CIBI Scores from Parallel, Placebo-Controlled Phases of Protocol CI-970-61
   - Summary of Linear Models Analyses of ADAS-COG and CGIC Scores from Three Placebo Controlled, Enrichment Studies of Tacrine
   - Clinical Pharmacology
-Life Table Analysis of Time to First Clinical Response Protocol CI-970-61
-Comparisons of Improvement vs. No Improvement for ADAS-COG (4 or More Point Reduction over Baseline) Protocols CI-970-01, -04, and -06
-Life Table Analysis of Time to First Clinical Response Protocol CI-970-26
-Experimental Design

7. Carl Peck’s Oncology
8. Georgetown University Medical School Center for Drug Development Science
   -handwritten notes on Georgetown letterhead
   -Carl Peck’s Oncology papers
   -email from Karl Peace to Carl Peck on Intrinsic Efficacy
   -email from Karl Peace to Carl Peck on combination Drug Development
   -Clinical Development of Oncologic Agents: Challenging the Tradition
   -Speaker Biographies
   -Clinical Development of Oncologic Agents: challenging the Tradition
9. Presentation at Princeton-Trenton chapter
   (loose items)
   -handwritten notes on Marriott Hotels and Resorts letterhead
   -Welcome to “Dose Response Clinical Trials” November 15-16, 2004
   -Abstract From: American College of Gastroenterology
   -list of names
   -email from Joe Mason to Karl Peace about Barnett Internationals
   “optimizing Dose…” conference information (BI-443)

10. Dose Response Meeting
    -not in folder- Dose response papers
    -not in folder
    -PMA Education and Research Institute (Peri) Training Course in Non-
      Clinical Statistics January 9-11, 1991

11. Dose Titration

9. Box 13: Meetings
1. 1986 Session on Draft Guideline
2. Chicago Session on Content and Format of the Application
   - Research/Meetings –ASA Chicago Session
3. 1986 Annual Joint Meeting, Chicago August 17-21
   - Empty
4. 1986 Joint Meeting, Continuing Ed Subcommittee Meeting
   - ASA-Annual Joint Meetings
5. Executive Committee Meeting-1986 Joint Meeting
   - ASA-Annual Joint Meeting
6. 1986 Joint Meeting, Session on the Clinical Guidelines
• ASA-Annual Joint Meetings
7. DIA BA/BE Workshop/ 1991 August
8. Time to Event ADTE Methods
9. Design and Analysis of Bioavailability Studies 11/16/83
10. Design and Analysis of Bioavailability Studies 11/16/83
11. Safety Data Book Chapter
12. PMA Med Section Training Seminar

• Pharmaceutical Manufacturers

13. PMA Biostatistics Committee
14. 1986 ENAR-ALL

(loose items)
15. ENAR-3/18/86 Combination Drug Trials
16. 1986 Spring ENAR Meetings, Atlanta
  • Empty
17. 1987 Spring ENAR Meetings
18. Unlabeled
  • Continuous form stationary
19. 1989 Spring ENAR Meetings Lexington, KY

10. Box 14: MISC
   (loose items)
   • Handwritten note on Courtyard Marriott Stationary
   • Flash drive – Jiann-Ping Hsu College of Public Health
   • The Promise of Berkley Spring 2010
   • Punch cards
   • Clinical Trial Methodology CD

1. Dr. Peace-APHA
   (loose items)
   • Paid in Full: Baker county Native Releases New Book of Memoirs
   • Ga Southern Scholar Receives Award from Philippine Statistical Association
   • Drug information Journal Author Guidelines AIMS and SCOPE
   • Journal of Epidemiology and Community Health – printout
   • Statistical Methods in Medical Research
   • Instructions for Authors “What AJPH authors Should Know”
   • Submission Guidelines for ICSA Bulletin
• Protecting the Health of the Public – Institute of Medicine Recommendations on Drug Safety
• Applied Clinical Trials
• Email about Regulatory Affairs in Drug and Device Development – Gall for Manuscripts
• Renowned Scholar and Pharmaceutical Researcher Endows chair in Biostatistics at UC Berkeley
• Bioinformatics Internet Sites
• Proteinuria in Gold-Treated Rheumatoid Arthritis
• Safety of Drugs Is Indeed a Life Cycle Exercise
• The Role of Vasopressin in Maternal Separation-Induced Short-Term Consequences and Adult Depressive Profile
• Southeast (Waycross) Public Health District Perinatal and Premature Mortality Measures By Census Tract With County Commission Districts, 1998-2002
• Baseline Cumulative Hazards Graphs
• The Ten Commandments of Good Health-book
• The Claxton Enterprise
• Regents Launch Public Health Initiative To meet Increased Demand
• BookFinder4u.com page- Design and Analysis of Clinical Trials with Time-to-Event Endpoints (Chapman & Hall/ Crc Biostatistics Series)

2. Citations of K.E. Peace papers

(loose items )

• Parke Davis Opticals envelope
• Current Board of Visitors 1986-87
• Members of Board of Visitors Whose Terms Expire This Year and Are Not Eligible for Re-election
• Suggestions for Membership on the Board of Visitors form
• Letter form Katie Burkett PHSA President to Jiann-Ping Hsu College of Public Health Faculty and Staff
• Top 50 Georgia Foundations by Assets, circa 2003
• emails from Karl Peace –some links of interest re philanthropy
• Biostatistics
• Hot Topics in Clinical Trials-white binder
• Meta-Analysis: fundamentals to Recent Developments-blue binder
• Klonopin Dose Optimization Study – white binder
• Klonopin Dose Titration Study

(loose items)

• Statistics News printout
• Update on the Jiann-Ping Hsu College of Public Health
3. McNeil Course

(loose items)

• Determining the Optimal Dosage Regimen for H2-Receptor Antagonist Therapy-A Does Validation Approach
• The Pooling of Data from Multicentre Trials
• The Pooling of Data from Multi-Centre clinical Trials
• Sample size Considerations in Clinical Trials Pre-Market Approval
• The Impact of investigator Heterogeneity in Clinical Trials on Detecting Treatment Differences
• Statistical Section of a Clinical Trial Protocol
• TMO: the Trial Management Organization – A New System for Reducing the Time for Clinical Trials
4. DIA 1991
5. Institute For Health, Policy And Evaluation Research
6. Clinical Trial Methodology Book
7. Kidney T.P. Data (L1970, 71970) and ATG Study Data

(loose items)

• Letter from Murl T. Wilson –attached – information regarding switch from RX to OTC marketing of Actifed, NDA’s 11-935 and 11-936
8. Artifacts/Book Reviews
9. Intrinsic Efficacy to Greg Campbell and Sue-Jane Wang
10. Unlabeled (grey folder)
    • Correspondence between "Brother Kao-Tai" and "Brother Karl" regarding joint research
11. TAS
    • Continuous form stationary
12. 1990 Princeton Conference
13. Calan Site Change Study
14. Articles Needed
15. John Marshall Article

(loose items)

• Past and Present Regulatory Aspects of Drug Development
• An Overview of the Processes of Discovery, Basic Research, Clinical Development, & Manufacturing, In Pharmaceutical Development With Attention to Bio statistical Considerations

16. Box 15: Biology
   1. Bioinformatics/Genomes
   
   (loose items)
   
   • Statistical Considerations in the Design and Analysis of H.R.T. Study 376-368
   • Drug Development Strategies For Subpopulations
   • Introduction to SAS
   2. Problem with Harsi Patel
   3. Special issue of JASA Radio Paper
   4. Bioequivalence
   5. CIBA Vision Talk
   6. History of Biopharmaceutical Section of ASA
   7. A Pharmaceutical Model with Covariates or Cox’s Procedure? July 16, 1984
   8. Statistical Services Department Agenda
   
   (loose items)
   
   • Biopharmaceutical Report Fall 1992
   • Biopharmaceutical Report Fall 2000
   9. FDA Bio equivalency Workshop on Solid Oral Dosage Forms 9/29, 30, 10/1/86
   10. On the Analysis of Ratios in Bioequivalence Testing 10/5/85
   11. Course: George Washington University

17. Box 16: Teaching
   1. Unlabeled
      • Overview of Clinical Research Data Processing
   2. Workshop on Clinical Trials 12/8-9/83
   3. Clinical Trials Workshop for U.K. And European Participants May 31, 1984
   5. Aspects of the Clinical Trials Workshop at Smith Kline and French Labs April 19, 1983
   6. Finite Markov Chains and Stochastic Processes with Applications: Sibbing Gas Diffusion And Chemical Kinetics
(loose items)

- Survey of Frequency of statistical Analyses
7. Parke Davis: Biometric Standards
8. Educational Materials for Individual Instruction June 1, 1984
9. Biometric Standards Poo

(loose items)

- Statistical Analysis
- References
- A Characterization of the Effect of Varying Sample Sizes, Subject to a Fixed Total, on Detecting a Difference in Two Means
- Coding/Supply Memo
- Statistical Analysis Plans (SAP)
- Issues in Data Monitoring And Interim Analysis In The Pharmaceutical Industry
- Searle Memorandum
- A Test For Differences Between Treatment Means When Several Dose Levels Are Compared With A Zero Dose Control
- The comparison of Several Dose Levels With A Zero Dose Control
- A Non-Parametric Equivalent of Williams’ Test for contrasting Increasing Dose Levels of a Treatment
- Analysis of Data from Multiclinic Trials
- Statistical Input into the Design and Analysis of Bioavailability Studies
- Organization of Ann Arbor Statisticians Proceedings
- Sample Compare Program
- Memo to Biometrics staff from Wayne about Multicenter Studies- Are More Subjects Always Better? (Or, What’s the Effect of Centers with Few Patients)
- Standard Analyses - Basic Hypotheses, CLs, and Type 1 Error Rates
10. Experimental Design by Box & Hunter
11. Biostatistics
12. Meta-analysis Chapter Correspondence
13. Meta-analysis Manuscripts-Peace
14. Unlabeled
- Methods for Interpreting and Combining Experimental Results
15. On Combining P-U Alues
16. Meta-Analysis Literature Search

(loose items)

- Ulcer Disease: Investigation and Basis for Therapy
- Correspondence between Edward A. Swabb to Karl E. Peace
- Correspondence between Tom Teal and Karl E. Peace
- Cost-Effectiveness in treatment of Peptic Ulcer Disease
- Meta-analyses in Ulcer Disease

17. Bioavailability

(loose items)

- Report of The Workshop on Controlled Release Dosage Forms: Issues and Controversies
- Slides on bioavailability

18. Karl Peace

19. Parke-Davis Highlights

18. Box 17: Manuscripts

1. Perry, M: Health and Wellness in Residents Who Matriculate into Physician Training Programs acknowledgement paper

(loose items)

- Summary of Gart's Paper
- Division of Clinical Pharmacology

2. Medical College of VA Seminar 2/17/95
3. Clinical Research

- Hard copies of slides

4. AJPH Paper: Validity of PH Intervention
5. TTE: Permission verification
6. Contributor Agreements
7. TTE
8. Making Informed consent More Ethical DIA Forum
9. Letter to Editor PHARMA DD
10. Degrees of Freedom in a Nonparametric Test (Letter to Editor-Biometrics)
11. Racial Differences in Perception of Breast Cancer Risk in Rural Southeast Georgia (JGPHA)
12. Nonclinical Statistics Course

(loose items)
• Research Ethics Timeline
• The New England Journal of Medicine
• The New England Journal of Medicine Special Report
• Teaching Statistics to Medical Students Using Problem-based learning: The Australian Experience
• Fundamentals of Clinical Trials
• Chapter 3 Sample Size Considerations in Clinical Trials Pre-market Approval
• Chapter 8 Clinical Trials in the Treatment of Panic Disorder
• Taylor and Francis Books, Inc.

19. Box 18: Manuscripts

1. GPHA “Validity”

(loose items)

• Biostatistical Aspects of the Analysis and Interpretation of Cancer Clinical Trials
• Monitoring Adverse Experiences in Clinical Drug Development
• The Pooling of Data from Multicentre Clinical Trials
• Interim Analyses: p-Value and Power Computations in Multiple Look Trials
• Biostatistical Aspects of Development of Drugs to Treat Alzheimer’s Disease Based Upon enrichment Designs

2. Pharmaceutical Classification of Bipolar Disorder” – MCG Seminar
3. MCG MTG re Bipolar
4. Equilibrium-Based Bipolar Neurological Modeling

(loose items)

• Practice Guideline for the Treatment of Patients with Bipolar Disorder
• Letter from Karl E. Peace to David J. Kupfer about Equilibrium-based Bipolar Dynamic Model
5. Bio.I.T Word
6. DIA
7. Bipolar Conference Pittsburgh 6/8-9/07
8. ICSA – 2007

20. Box 19: Meetings

1. American Society of Hospital Pharmacist (ASHP) Meetings
2. Society for Pharmaceutical Medicine August-September 1988
3. Regulatory Affairs Professionals Society (RAPS) Meetings
4. BRCI Computer Manual
5. Clinical Research Data Processing Book Project
6. American Association of Pharmaceutical Scientist (AAPS) 1989
7. Princeton Conference 1974
8. American Society of Clinical Oncology (ASCO) Meeting 1978
10. Gynecologic Oncology Group (GOG) (Phoenix) 1980
11. Second International Conference on Adjuvant Therapy of Cancer 1979
13. Midwest Biopharmaceutical Statistical Workshop-Muncie Meeting
14. Regional Meeting of Pharmaceutical Statisticians and Data Processors
15. The Scientist Newspaper
16. Pulmonary—Allergy Drugs Advisory Committee 18th Meeting
17. Third Annual Society For Clinical Trials Meetings
18. Society for Clinical Trials Meetings May 2-5, 1982
19. Society for Clinical Trials May 9-13, 1981
20. Society for Clinical Trials Workshop Proposals for 4th Annual Meeting
21. American Society for Quality Control (ASQC) TAPPAN ZEE Section April 22, 1983
22. Pharmaceutical Industry Statisticians (PIS)
25. 1984 Spring ENAR Meetings and Orlando American Statistical Association (ASA) Meetings Scientific Affairs
26. 1984 Joint Meeting, Philadelphia ASA Annual Joint Meeting Scientific Affairs
27. 1985 Spring ENAR Meetings, Raleigh ASA
ENAR Meetings Scientific Affairs
28. 1985 Annual Joint Meeting, Las Vegas ASA
29. Summary of ASA Biopharmaceutical Section 1985
30. American Statistical Association (ASA) Background and Etiology
31. 1985 ASA Meeting

Box 20: Manuscripts

1. Equilibrium-Based Bipolar Neurological Modeling
2. Ying-Yang Papers and Research
3. Tacrine/ Alzheimer Papers
4. Summary of the effectiveness of Tacrine
5. ANCOVA Analyses

6. Food and Drug Administration and Peripheral and Central Nervous System Drugs Advisory Committee
7. Population PD/PK
8. Tacrine Meeting 1993
9. Yin Yang Papers and Research 2
10. Ying-Yang Modeling of Bipolar Disorder
11. Yin Yang Dynamic Neurological Modeling and Diagnostic Analysis of Major Depressive and Bipolar Disorders
13. Analytical/ Physical Chemistry Seminar March 1983

Box 21: Meetings

1. 1987 Annual Joint Statistical Meetings
2. An Analysis of Data on spontaneous Duodenal Ulcer Recurrence and Template
3. Federal Drug Administration Papers
4. Drug Information Association Workshops
5. Statistical Analysis of Protocol: U20-86-02-005: Comparison of In the Treatment of
6. Hypertensive Patients
8. Draft Guide For the Format and Content of the Statistical Section of An Application June 1985 and January 1986
9. Handbook of Biopharmaceutical Statistics in Human Drug Development
10. Handbook of Biopharmaceutical Statistics in Human Drug Development Chapter Contents
   a. Correspondences on Chapters in Biopharmaceutical Statistics in Handbook of Biopharmaceutical Statistics and Drafts
   b. American Statistical Association 1984 Proceedings of Biopharmaceutical Section
   c. Statistics in the Pharmaceutical Industry
   d. Letter to Volker W. Rahlfs from Karl E. Peace
   a. Includes Articles and Drafts of papers with Correspondences
      i. To Joan Godbee
      ii. To Elsie Peace
      iii. To Christopher Peace
      iv. To Nora Coury
      v. To M. T. Roberson
      vi. To Mickey Peace
      vii. To Karl Johnson
      viii. To Ronald Moore
      ix. To Walter Lynch
      x. To Tom Semler
      xi. To Peggy Phillips
      xii. To Steve Hutcherson
      xiii. To Martha Watson
xiv. Michael Dey

c. Statistical Issues for Drug Research and Development No. 106

d. Statistical Issues in Drug Research and Development Letter from Marcel Dekker to Karl Peace December 12, 1989

e. Statistical Issues in Drug Research and Development Letter from Sylvan Wallenstein to Sandra Beberman September 5, 1989

f. Statistical Issues in Drug Research and Development Letter from Sylvan Wallenstein to Rebecca Bernstein August 20, 1989

g. List September 18, 1989

h. Statistical Issues in Drug Research and Development Fax to Sylvan Wallenstein from Sandra Beberman and Preface September 18, 1989

i. Package Receipt September 6, 1989

j. Statistical Issues in Drug Research and Development fax to Sylvan Wallenstein from Sandra Beberman August 30, 1989

k. Statistical Issues in Drug Research and Development fax to Rebecca Bernstein from Sylvan Wallenstein August 20, 1989

l. Letter to Sylvan Wallenstein from Karl Peace August 14, 1989

m. A Critique of the Grizzle, Balaam, and White Designs August 16, 1983

n. A Two Treatment, Two-Period, Crossover Design Permitting Assessment of Direct and Carry-Over Effects May 26, 1981

o. Letter to Sylvan Wallenstein from Karl Peace December 29, 1988


r. Letter to Karl Peace from Harji Patel

s. Package Receipt August 14, 1989

t. Letter to Rebecca Bernstein from Karl Peace June 22, 1989

u. Letter to Karl Peace from Rebecca Bernstein June 21, 1989

v. Letters Concerning Statistical Issues in Drug Research and Develop

i. To Karl Peace from Rebecca Bernstein August 2, 1989

ii. To Sylvan Wallenstein from Rebecca Bernstein August 2, 1989
iii. To Karl Peace from Rebecca Berstein July 12, 1989
iv. To Karl Peace from Henry Boehm July 20, 1989
w. Letter to Karl Peace from Bill July 25, 1989
x. Letter to Karl Peace from Donald M. Stablein July 18, 1989
y. Letter to Karl Peace from Martha S. Hearon July 21, 1989
z. Letter to Karl Peace from Gerald M. Fava
aa. Letter to Karl Peace from Morris Meisner July 17, 1989
bb. Letter to Karl Peace from Joseph K. Haseman July 25, 1989
c. Letter to Karl Peace from Lloyd Fisher July 25, 1989
dd. Letter July 31, 1989
e. Letter to Karl Peace from Robert Makuch
ff. Package Receipt August 2, 1989
gg. Analysis of Crossover Designs When the Errors Are Not Independent
hh. Contract between Marcel Dekker, INC and Karl Peace November 17, 1989
i. Contract between Marcel Dekker, INC and Karl Peace January 12, 1988
jj. Hypothesis Testing for Combination Treatments May 9, 1989
kk. Testing Whether an Identified Treatment is Best May 5, 1989
ll. Statistical Assessment of Combination Drugs
mm. Analysis of Crossover Designs When the Errors are Not Independent January 30, 1989
nn. Loyd Fisher Floppy Disc


14. Correspondence of Results of the ASA Biopharmaceutical Work Groups May 1985

15. Correspondence Pertaining to the Publication of ASA Workshop Volumes
   Sesquicentennial Celebration December 29, 1988

16. Presentations and Guidelines
   a. ASA Continuing Education Workshop Preparing the Statistical Section
      Under the New Drug Application (NDA) Rewrite August 15, 1987
b. An Outline of the Statistical Section of a New Drug Application August 15, 1987

c. Preparing the Statistical Section Under the NDA Rewrite

d. Objective

e. Draft Guideline for the Format and Content of the Statistical Section of an Application June 1985

f. Draft Guideline for the Format and Content of the Clinical Data Section of an Application January 1986

17. Correspondences 1986-87

18. Integrated Report

19. Correspondences and Papers 3

   a. Correspondences 1985-1990
   

   c. Guide for Authors and Editors

Box 22: Transparencies

1. Transparencies 1

   a. Biostatistical Aspects of Development of H2 Receptor Antagonist Drug to Treat Duo Denal Ulcers

   b. Biostatistical Aspects of Clinical Research Programs

   c. Design and Analysis of Pivotal Trails to Assess Efficacy of Drugs to Treat Panic

   d. Clinical Trials in Prevention of NSAID Induced Gastric Ulceration

2. Transparencies 2

   a. Biostatistical Input to the Design, Analysis and Interpretation of Cancer Clinical Trials

   b. A Short Course on the Design analysis and Interpretation of Cancer Clinical Trials

3. Transparencies 3

   a. Drug Development Type of Trails

   b. Biological Test Systems

   c. Clinical Development Biostatics Tutorial
d. Preclinical Safety Development

e. Characterization of a Drug and Its Doses

4. Transparencies 4
   a. Bioassay, Drugs, and Doses
   b. Clinical Efficacy Trial with Quantitative Data
   d. Placebo Comparisons inactive-Controlled Trials Notes for Princeton Conference Tutorial December, 1987
   e. Draft
      i. Biotechnology and Biostatistician

5. Transparencies 5
   a. Genetics and the Future of Medicine

6. Transparencies 6
   a. Corse Outline: Statistical Issues in Drug Research and Development
   b. Dual Control Groups in Rodent Carcinogenicity Studies
   c. Statistical Methods for a Three-Period Crossover Design in Which High Dose Cannot be Used First
   d. Active Control Equivalence Studies
   e. Biostatistical Aspects of the Development of Anti-anginal Drugs: A Phase II Trial Incorporating an Equiradial Hexagonal Design with RSM
   f. Intention to Treat In Clinical Trials
   g. Dosing in the Elderly

7. Julie Achatz/ Klugh
8. Emily Clark/ Klugh
9. Shawna Hedin/ Klugh
10. Rachel Hemberger/ Klugh
11. Olivia McCallum
12. Jon Mann Protocol
13. Diet Product Development
14. Request to Industry
15. Lan-DeMets PGM

16. Integrated Research
   a. Contains correspondence
   b. The Center for Rural Health and Research
   c. The Use of Nuclear Protein-encoding Genes, RNA Polymerase II Tick Molecular Systematics

17. Correspondences, Schedules, and Check
   a. Correspondences 2003
   b. Schedules
   c. Check from Johnson and Johnson
   d. List of names

18. Transparencies 7
   a. Biostatistical Aspects of Development of Drugs to Treat Alzheimer's Disease Based upon Enrichment Designs
   b. Analysis and Summarization of Safety Data Collected in Clinical Trials
   c. The Polling of Data from Multicentre Trials
   d. Monitoring Adverse Experiences in Clinical Drug Development

19. Transparencies 8
   a. Includes Correspondence September 15, 2000
   b. Department of Health and Human Services
   c. Preclinical Safety Development
   d. Pharmaceutical Formulation Development
   e. Biopharmaceutical Statistics for Clinical Drug Development

20. Papers
   a. Clinical Efficacy Trials with Quantitative Data
   b. Analysis of Ratios and Decision Rules in Bioequivalence Studies
   c. Additional Topics
   d. Mini Course-Drug Metabolism and Pharmacokinetics

Box 23: Data

1. Paris NSAID Meeting December 5-8, 1987
   a. Correspondence December 3, 1987
b. CYTOTOEC (MISOPROSTIL) NSAID Etude Rapport Qualite-Prix Cost Effectiveness Study
c. Tables
d. Slides
2. Deerhurst Symposium Administration Meeting
   a. Comparative Assessment of Spontaneous Relapse Rates after Healing Active duodenal Ulcers with Misoprostol or Other Agents: A Literature Survey Draft February 16, 1987
   b. Acute D.U.
   c. Cytotoec Advisory Board meeting November 19-22, 1987
   d. The Treatment of Gastric Ulcer with Antisecretory Drug: Relationship of Pharmacological Effect to Healing Rates Manuscript
   e. Duodenal Ulcer What Comes After Healing
   f. Smoking and Ulcer Healing Charts
g. Map of Toronto
h. Receipt
   i. Correspondence 1986-1987
   j. Baseline Description G. D. Searle and Co. Table 1-a
   k. Baseline Description G. D. Searle and Co. Table 1-b
3. Relapse Poop Slides
4. Rheumatologist Symposium
   a. Correspondences 1987
5. Cytotoec Advising Board Meeting November 18-23, 1987
   a. Slides
   b. Slides Print Outs
   a. Seminar March 6, 1980
      i. Printout and Charts
   b. Survival Data Analysis User’s Guide
   c. BMDPIL Life Tables and Survival Functions Health Sciences Computing Facility November 1978
7. VCU Career Day March 19, 1982
   a. Schedule
   b. Careers in Statistics
c. Slides Careers in Statistics
8. PMA Seminars
   a. Framed Congratulatory Letters
      i. University of California, Berkeley September 3, 2009
      ii. North Georgia College and State University October 21, 2009
9. Basic Statistics Course for Clinical R and D May 1983
a. Correspondence 1983
b. Transparencies
   i. Basic Statistics Course
c. Contents
d. Schedule
   a. General Information on the Workshop at Ball State University
   b. Correspondence 1983
   c. Job Request
   d. The PHGLM Procedure
   e. Data set for MBSW Example of Repeated Significance Testing March 2, 1983
   f. Gold Data Salt Lake for Protocol 20
   g. Uni-Coll Corporation Expansion of Networking Services
   a. Transparencies
      i. Muncliffe Study May 24, 1983
   a. Reprographic Services Quality Control Checklist
   b. Tables
   c. Appendix 2
   d. Stepwise Proportional Hazards General Linear Model Procedure 1975-1978
   e. Patient Accountability 1973-1983
13. Analysis of Survival Data Course
14. Non-Sequential Analysis of Time to Event Data Seminar March 1984
   a. Now. Parametric Methodology
   b. Distribution Lists
   c. Memos 1984
15. Non-Sequential Analysis of Time to Event Data
16. Non-Sequential Analysis of Time to Event Data Seminar
17. Transparencies
   a. Also has paper print form
18. Survival Data Analysis Methodology 4-25-1984
19. Transparencies
   a. User Guide
20. Reducing Sample Size Through Sequential Analysis
   a. Reducing Sample Size Through Sequential Analysis Transparencies
21. Notes on Owner Guide
22. Analysis of Survival Data Course
23. Survival Data Analysis Methodology April 25, 1984
   a. NTP Carcinogenesis Bioassay
   b. Carcinogenesis Bioassay of L-ASCORBIC Acid (Vitamin C) (CAS NO. 50-81-7) in F344/N Rats and B6C3F1 Mice (Feed Study)
24. Correspondence and Manuscripts
   a. Correspondence 1987
   b. Manuscript
   c. Statistical Analysis of Protocol U81-86-02-001: Comparison of Two Dosing Regimens of Misoprostol as Therapy for Duodenal and/or Gastric Ulcer Disease
25. Statistical Report Outline Administration
   a. Integrated Report
   b. Correspondence 1986
   c. Manuscript
   d. Statistical Report Outlines
   e. Integrated Report 2
   f. Integrated Report 3
26. Research Reports of Clinical Investigation
27. Technical Operations Type Org.
   a. Corporate Medical and Scientific Affairs Department of Clinical Data Information Management
   b. Manager, Clinical Efficiency and Safety Coordination
   c. Correspondence 1987
   d. Corporate Medical and Scientific Affairs Biometrics
   e. 1988 Goals and Strategies
   f. 1988 Operating Plan Corporate Medical and Scientific Affairs
   g. Examination of the Information Management and Analysis Requirements of the Scientific Affairs Division of G.D. Searle
   h. G. D. Searle and Company Definitions of Performance Rating Executive/Exempt

Box 24: MISC

1. 2x2 Crossover Design
2. Correspondences and Papers
   a. Papers
      i. The Treatment of Gastric Ulcer with Antisecretory Drugs: Relationship of Pharmacological Effect to Healing Rates
ii. Protocol Effect of Sleep Reversal on Gastric Secretion Before and After a Two Week Period of Night-Shift

iii. A Model for Definition of Optimal Dose Size and Frequency of Antisecretory Drugs in Duodenal Ulcer

b. Correspondence 1986
c. Directions to Deerhurst, Ontario, Canada
d. Deerhurst VactionVillas
   i. Pamphlets
   ii. Map
   iii. Correspondence 1986
   iv. The condominium and Timesharing Magazine
   v. Information Sheet

3. Clinical Guideline DIA Workshop May 5-6, 1986
   a. Correspondence 1986

4. DDW San Francisco May 17-22, 1986
   a. Correspondence 1986
   b. Cimetidine 800mg h. s. in the Treatment of Gastric Ulcer
   c. Digestive Disease Week May 18-21, 1986
   d. Programs

5. Influencing Colonoscopy Screening in Rural Southwest Georgia: A Pilot Study

6. Dose Proportions MS.

7. Papers
   a. Alternate Solution
   b. To the Readers of the American Statisticians

8. Southwest Georgia Cancer Coalition
   a. Agenda
   b. Baker County Cancer Screening and Navigation Pilot Program Evaluation
   c. Baker County Cancer Screening and Navigation Program Evaluation Executive Summary
   d. Baker County Screening and Navigation Project Client Demographics January 2006- July 2007 Tables
   e. Criteria Rubric for Replication of Baker County Screening and Navigation Project
   f. Baker County Cancer Screening and Navigation Program Evaluation Report


10. Course Director
a. Correspondence 1989
b. Linear Regression Analysis of Censored Data April 11, 1990
11. Publications AY 07-08 Yin Yang
   a. MentalSquare- An Equilibrium-Based System for Biopolar Neurobiological Pattern Classification and Analysis
   b. JSM 2007 Online Preliminary Program
   c. Some Thoughts on the Assessment of Pharmaceutical Safety Data
   d. List
   e. Georgia Public Health Association (GPHA) 78th Annual Meeting and Conference
12. SAS PC Table Programming
   a. Floppy Disks (5 ¼")
      i. SAS Programs Copied from C Drive m-Mead M-MICUSAS...
      ii. SAS Tables
   b. M_TDEMO SAS B1 VM/IS RELEASE 4.0 CMS
   c. M_MCH SAS B1 VM/IS RELEASE 4.0 CMS
   d. M_MEANO SAS B1 VM/IS RELEASE 4.0 CMS
   e. M_MEAN SAS B1 VM/IS RELEASE 4.0 CMS
   f. M_MEANO
   g. M_TDEMO
   h. Drug vs. Placebo vs. Active
      i. Listing of Week 0 Data Set “Derived”
   j. M_MCHSAS
   k. M_MEAN
   l. SAS Table 1 Descriptive Statistics of Seven Primary Efficacy Variables at Baseline (B)
   m. SAS ® Proprietary Software Release 6.03
   n. Fax 1991
   o. VSHIELD Version 3.6V77
   p. BRCI’s Systems Configuration Flow Chart
   q. Program TAB16FIN.PRG
   r. Program TAB15FIN.PRG
   s. Program TAB9FIN.PRG
   t. Summary Statistics for TRT BY GLRSPV2 Controlling for INVNO
   u. % Pagenum Instructions
   v. Floppy Disks (3.5")
      i. Maureen Simmonds Ts. PRN
      ii. Untitled (3)
   w. The Coding Symbol is for a Thesaurus of Adverse Reaction Terms (COSTART)
x. Code (2)
13. On Using One Coefficient Variation for Sampling Size Determination
14. Ulcer
   a. Usefulness of Anti-Ulcer Drugs for the Prevention and Treatment of Peptic Ulcers Induced by Low Doses of Aspirin
15. What a World Class Community Research Program Would Look Like
   a. Definitions of Risks
   b. Design Overview
17. Design and Cost Considerations of One Trial K Comparisons vs. K Trails with one Comparisons
18. Correspondence and Papers
   a. Effect of Two Cimetidine Regimens on Prothrombin Time and Warfarin Pharmacokinetic During Long Term Warfarin Therapy
   b. American Society for Clinical Pharmacology and Therapeutics Abstract Form American College of Gastroenterology
   c. Correspondence 1983; 1989
   d. An Evaluation of Triprolidine and Pseudoephedrine in the Treatment of Allergic Rhinitis
   e. Course/ Colloquy Proposal Form
   f. Protocol for Warner-Lambert/Parke-Davis Clinical Trial
   g. Warner-Lambert/Parke-Davis Pharmaceutical Research Division CI-719-GEMFIBROZIL
   h. Levene Test for Homogeneity of Variance
   i. Randomization Test for Schuirmann’s Two One-sided Tests T-Test for AUC
19. SNRT Data Analysis
   b. Data Female SNRT Data Input
20. Wright State University
   a. Problems to be Presented in Clinical Session on Biometrics
   b. C. R. Rao: Weighted Discrete Distributions
21. Helsinki Heart Study
   a. Helsinki Heart Study: Coronary Heart Disease Incidence During an Extended Follow-Up
   b. Helsinki Heart Study: An 8.5 Year Safety and Mortality Follow-up
   c. Correspondence 1992-1993
   d. Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population
e. Statistical Analysis Methods for Providing Inferences Between Primary Response Measures and Exposure to Study Medication in the Helsinki Heart Study: Double Blind and Open Label Periods

22. An Alternative Way of Calculating the X² Independence or Association Test Statistic for a 2xk Contingency Table

23. PNAS Manuscripts Review and Revisions
   a. Classification: Medical Sciences Tacrine in Alzheimer's Disease: A Population Pharmacodynamic Model for Cognitive Effects; Methods, Part 1 of 2
   b. Classification: Medical Sciences Tacrine in Alzheimer's Disease: A Population Pharmacodynamic Model for Cognitive Effects; Methods, Part 2 of 2
   c. Correspondence 1992

24. Correspondence and Data
   a. Efficacy Summary File for the Bacteriologic Response Visit
   b. Correspondence 1985
   c. Data Set M030EFF.DAT
      i. Floppy Disk (5 ½)
   d. M85-129

25. Transparencies and Papers
   a. Correspondence 1984
   b. Distribution List

26. Non-sequential Analysis of time to Event Data Seminar July 1984

27. Non-sequential Analysis of time to Event Data Seminar July 23, 1984
   a. Transparencies
   b. Data Analysis

28. Survival Data Analysis Methodology April 25, 1984

29. Colon Carcinoma Exercise
   a. Clinical Trial Analysis Colon Rectal Cancer
   b. Correspondence 1984
   c. Distribution List
   d. Current Research on Antineoplastic Agents
   e. Antibiotics Screen
   f. Dual Process

30. Survival Data Analysis Seminar II

Box 25: Manuscripts

1. Correspondence and Papers
   a. Survival Data Analysis Correspondence 1982-1983
   b. Lectures 1-7
c. Independent Study with Bobbi Scueftler 1983

d. VMSP Conversational Monitor System

e. G.M.T. Was the Origin

f. Lectures 7-11

g. Survival Analysis: Midterm Exam October 20, 1981 MCU Biostatistics

h. Re Goodness of Fit

i. Use of the Modified Sauage Statistics in Testing Sequentially the Equality of Two Survival Distribution

j. BIS: 600: Final Examination: MCV Richmond, Virginia 23298

k. Analysis of Survival Data Chapters and Biblocist

l. Mortality Table

m. The Mean and Variance of $\hat{S}_T$

n. Connection Between the Mantel-Haenszel and Cox Procedures for Two Sample Case December 17, 1979

o. Test of Hypothesis in 2x2 Tables

p. Situation

q. Computation

r. Marginal Likelihood of Kalbfleisch and Prentice (1973) for continuous Time and Non censored Case

s. Test of Significance

t. The Feigl and Zelen Data

2. Susan Arnold Memorial Project

3. Memorial Shelly Helmstrom

4. Memorial Melissa Giariatataro

5. Memorial Peter Settevendemie

6. Heidi Oh Memorial Consulting

7. Ifath Hopkins

8. Melissa Decker

9. SEGACA: Survey Methodology Group

10. Memorial Consulting: Dr. Eunice Bell

11. Memorial Consulting Michelle Stevens

12. Research Protocol with Bill (William) Hoskins

13. NCIR 25 Grant Norma Sheridan-Leos

14. Comprehensive Screening and Management of Distress Norma Sheridan-Leos

15. Biostatistical Aspects of Clinical Drug Development

16. Chapters

   a. Chapter 6 Overview of Bayesian Inferential Methods Including Time-to-Event Endpoints
b. Chapter 13 Design and Analysis of Cardiovascular Prevention Trials

c. Chapter 14 Design and Analysis of Antiviral Trials
   i. Includes a CD

17. Maximum Likelihood Estimation and Efficiency Assessments of Tests of Hypotheses on Survival Parameters

18. Eric V. Slud
   a. Chapter 5 Overview of Inferential Methods for Categorical Time-To-Event Data
      i. Includes a Floppy Disc

19. Clinical Trials Methodology
   a. Clinical Trials Methodology: A Graduate Course in Biostatistics for Medical Personnel
      i. Includes Transparencies
   b. An Overview of the Processes of Discovery, Basic Research, Clinical Development and Manufacturing, In Pharmaceutical Development

20. PowerPoint Presentations
   a. IV. a: Bioavailability and Bioequivalence of Pharmaceutical Formulations
   b. The Design and Analysis of Pivotal Clinical Trials to Assess the Efficacy of Drugs to Treat Panic Disorder
   c. Clinical Trials in the prevention of NSAID Induced Gastric Ulceration
   d. The Importance of Numbers (of Patients) in Cancer Clinical Trials
   e. Biostatistical Aspects of the Design of Cancer Clinical Trials
   f. Biostatistical Aspects of the Analysis and Interpretation of Cancer Clinical Trials

Box 26: Misc

1. Framed Photos and Awards
   a. Tito Mijares Lifetime Achievement Award
   b. Georgia House of Representatives 2008
   c. Thank-You Letter
   d. Dr. Bill Hoskins
   e. Dr. Phil Geetia
   f. Letter April 18, 2006

2. Statesboro Magazine January/February 2011
   a. Contains an Article about Karl Peace

3. PowerPoint Presentations 1
a. Introduction to Design of Genomic Clinical Trials
b. Targeted (Enrichment) Design
c. Categorical Data Analysis using SAS
d. Quantal Bioassay Analysis
e. The Final Session: Recent Topics in Categorical Data Analysis
f. Biomarker Adaptive Threshold Design
g. Development and Validation of Predictive Classifiers Using high Dimensional Data
h. Proportional Odds and Generalized Logits Models
i. Weighted Least Squares for Mean Scores
j. Poisson Regression

4. Considerations for Colorectal Cancer Screening

Box 27: Jiann-Ping Hsu

1. Framed
   a. Congratulatory Letter from Georgia Southern University
   b. Photo of Karl Peace’s Home from Age 10-18
   c. Elsie Peace 1974 Sketch of Home Karl Peace (son) was Born
   d. Philippine Statistical Association Certificate of Appreciation

2. BASS Short Courses and Tutorials

3. Magazines
   b. Newsboy March-April 2014
   e. Drug and Development January 2014 and March 2014
   g. Applied Clinical Trials December 2013-March 2014
   h. Significance December 2013 and February 2014
   i. Georgia Back Roads Summer 2012 and Spring 2014

4. Investing in Public Health 85th Annual Meeting and Conference of the Georgia Public Health Association

5. Graduate School Correspondence for Jiann-Ping Hsii

Box 28: Misc

1. Framed
   a. Ernest Karl Peace High School Diploma 1959
   b. Vanderbilt University Graduate Summer Session of Statistics in the Health Sciences 1975
   c. Karl Ernest Peace Clemson University Master of Science Degree 1964
d. Thank you from AAPS Atlanta October 1989  
e. Alumni Award  
f. Omicron Delta Kappa Certificate 2000  
g. Letter about the Philippine Statistician’s Tito Mijares Lifetime Achievement Award  
h. Georgia Southern College Bachelor of Science Degree 1963  
i. Who’s Who Among Students in American Universities and Colleges 1962-63  
j. Georgia Southern College Excellent Scholarship 1962  
k. Letter about Virginia Commonwealth University’s Founders’ Society  
l. The Philippine Statistical Association Certificate of Appreciation 2004  
m. Regulatory Affairs Professionals Society (RAPS) Membership Certificate 1989  
n. Letter from Jiann-Ping Hsu  
o. Letter about Chair-Elect Position from American Public Health Association 2009  
p. The Drug Information Association Certificate 2003  

Box 29: Books  

- Reference books  
  o SAS reference books x 7 (Different Volumes and Topics)  
  o User’s Guide to Survival Data Analysis  
  o Biopharmaceutical Statistics for Drug Development  
  o Statxact User’s Guide  
  o Resampling Stats  
  o Teledata Manager  

- Misc books  
  o Various magazines mentioning Karl Peace and the JPH College of Public Health  
  o Auto Auction Magazine  
  o Pencil Broadside Sketchbook  
  o User’s Digest 4th ed.  

Box 30: Framed materials  

- Awards x 10  
- Photographs x 5  

Box 31: Misc  

- Books
○ Idyll’s of the King
○ Key to Robinson’s Progressive Practical Arithmetic
○ Tennyson’s Princess
○ Irving’s Sketchbook
○ Condensed Books (A collection of stories)
○ Course in General Chemistry
○ Trigonometry for Secondary Schools
○ High School Physics
○ College Trigonometry

Box 32: Misc

- Cassette Tapes
  ○ Session 1: Integration of PapIn PK/PD Modeling
  ○ Session 1: Beyond Observational Data Analysis
  ○ A DIA PK/PD Workshop; Session 1 Basic Concepts and Applications
  ○ Sequence of period Effects
  ○ Log Transformation for Bioan. Bioeg Data
  ○ Outlier Analysis
  ○ A Session II: Individual Ratio Analysis
  ○ Log Transform
  ○ Sequence and Period Effects
  ○ Session IV: Impact on Drug Development
  ○ Session III: Design for Population PK/PD
  ○ Session II Modeling and Estimation Tape 2
  ○ Response to Industry Concerns on Early Termination of Clinical Trials
  ○ Session III: Simple Design Strategies for Poplu PK Model
  ○ Session II: Modeling and Estimation Tape 1
  ○ Session II: Appl. Of Popln PK/PD Analysis to Determine Optimal Dosing

- VHS Tapes
  ○ Gardner Communications “Vision”
  ○ Gardner Communications “Animation”
  ○ Health Care Industry
  ○ Gardner Communications “Imagination”
  ○ Demo Tape
  ○ Fresh Daily
  ○ S-Plus; Unopened/Still wrapped VHS
Box 33:

- Folder 1: Mathematical physiology: Summary of semester's work
- Folder 2: Mathematical physiology: Summary of semester's work continued
- Folder 3: Genetics 516 – Population genetics
- Folder 4: Genetics 516 – Population genetics continued
- Folder 5: Statistics 295 – Topics in Biostatistics
- Folder 6: ASA course: Analysis of survival data
- Folder 7: Comprehensives
- Folder 8: Continuous Form Paper
- Folder 9: Unbound notes
- Folder 10: BIY 646 – Nonparametrical statistics – notes
- Folder 11: BIY 646 – Nonparametrical statistics – problems
- Folder 12: BIY 600 – Hypothesis testing
- Folder 13: BIY 600 – Hypothesis testing – Notes, Roll, Reprints
- Folder 14: BIY 600 – Hypothesis testing – Notes, Roll, Reprints continued
- Folder 15: BIY 600 – Hypothesis testing – Notes, Roll, Reprints (3) continued
- Folder 16: BIY 600 – Hypothesis testing – Notes, Roll, Reprints (4) continued
- Folder 17: Gen 620

Box 34:

- Folder 1: 30th Annual Princeton Conference on Applied Statistics
- Folder 2: Dissertation draft
- Folder 3: Dissertation – Ch. 4 + 5 (draft)
- Folder 4: BIY 537 – Sampling theory
- Folder 5: Statistics 301 – Bayesian Interference
- Folder 6: Statistics 5020 – Time Series Analysis
- Folder 7: Statistics 5020 – Time Series Analysis continued
- Folder 8: Dissertation – Ch. 3 (draft)
- Folder 9: Exploratory Data Analysis
- Folder 10: Decision theory – Colloquy 254
- Folder 11: BIY 511 – Statistical Methods
- Folder 12: BIY 512 – Experimental design - notes
- Folder 13: BIY 512 – Experimental design – problems
- Folder 14: BIY 546 – Linear models – notes
- Folder 15: BIY 546 – Linear models – problems

Box 35:

- Folder 1: BIY 650 – Response Surface methodology
- Folder 2: BIY 650 – Response Surface methodology continued
- Folder 3: BIY 650 – Response Surface methodology (3) continued
- Folder 4: BIY 641 – Advanced inference
- Folder 5: BIY 641 – Advanced inference continued
- Folder 6: BIY 642 – Multivariate analysis
- Folder 7: BIY 642 – Multivariate analysis continued
- Folder 8: Statistics 300 – Actuarial functions – notes
- Folder 9: Statistics 300 – Actuarial functions – exercises
- Folder 10: Math 105 - Finite
- Folder 11: Colloquy 218 – Methods of Optimization
- Folder 12: Math 353 – complex variables
- Folder 13: Math 411 – Linear Algebra
- Folder 14: Math 453 – Advanced Calculus
- Folder 15: Math 453 – Advanced Calculus continued
- Folder 16: Math 371 – Probability
- Folder 17: Math 503 – Complex variables
- Folder 18: Math 505 – Problems and verification
- Folder 19: Math 504 – Complex variables
- Folder 20: Math 505 – Numerical analysis
- Folder 21: Math 505 – Numerical analysis – problem assignments
- Folder 22: Math 505 – Numerical analysis – Solved problem assignments
- Folder 23: Math 508 – Fourier Series - notes
- Folder 24: Math 508 – Fourier Series - solved problems
- Folder 25: Vector analysis
- Folder 26: Math 704 – Stochastic processes
- Folder 27: Math 801 – Linear Hypothesis – notes
- Folder 28: Math 801 – Linear hypothesis – Problems and proofs

Box 36:

- Folder 1: Math 802 – Linear Hypothesis
- Folder 2: Math 821 – Real Variables – notes
- Folder 3: Math 821 – Real Variables – Problems and proofs
- Folder 4: Math 822 – Real Variables
• Folder 5: Math 871 – Topology – Notes, Problems, Proofs
• Folder 6: Math 905 – Decision theory – Problems and proofs
• Folder 7: Faculty Seminar – Number theory
• Folder 8: Assorted notes
• Folder 9: Math 105 – Mathematics for Elementary teachers
• Folder 10: Statistics
• Folder 11: Math 110 – Introduction to probability and statistics
• Folder 12: Math 110 B-D – statistics
• Folder 13: Math 110 G – Statistics
• Folder 14: Math 211 Introductory Calculus
• Folder 15: Math 212 – Introductory Calculus
• Folder 16: Math 212 – Introductory Calculus continued
• Folder 17: Math 214 – Multivariable Calculus
• Folder 18: Math 222 – Math of Finance
• Folder 19: Math 310 – Differential equations
• Folder 20: Math 372 – Statistics (first half)
• Folder 21: Math 372 – Statistics (Second half)
• Folder 22: Math 402 – Probability
• Folder 23: Math 403 – Statistics – notes
• Folder 24: Math 403 – Statistics – solved problems and theorems
• Folder 25: Math 420 – Vector analysis
• Folder 26: Math 454 – Advanced Calculus – Ch. 8 outline and proofs
• Folder 27: Math 503 – Calculus of finite differences

Box 37:

• Folder 1: Math 872 – Topology and topology seminar
• Folder 2: Math 891 – Research problems in statistics
• Folder 3: Math 981 – Mathematical Statistics
• Folder 4: Diamont Gerson, Cato, Peace and Perkins
  ○ “An Evaluation of Triprolidine and Pseudoephedrine in the Treatment of Allergic Rhinitis”
• Folder 5: Holford and Peace Articles
  ○ “The Effect of Tacrine and Lecithin in Alzheimer’s Disease”
  ○ “Methodologic Aspects of a Population Pharmacodynamic Model for Cognitive Effects in Alzheimer Patients Treated with Tacrine”
○ “Results and Validation of a Population Pharmacodynamic Model for Cognitive Effects in Alzheimer Patients Treated with Tacrine”

- Folder 6: Lanza, Peace, Zimmermant Dickson
  ○ “Cost-effectiveness of Cimetidine and Misoprostol in Peptic Ulcer Disease”

- Folder 7: Peace Article
  ○ “The Alternative Hypothesis: One-sided or Two-sided?”

- Folder 8: Peace Article
  ○ “Clinical Studies: How to Successfully Resolve Clinical Problems to Achieve FDA Approval”

- Folder 9: Peace Article
  ○ Book Review of “The Design and analysis of Sequential Clinical Trials”

- Folder 10: Peace Article
  ○ “Design, Monitoring, and Analysis Issues Relative to Adverse Events”

- Folder 11: Peace Article
  ○ “Discussion for interim Analysis and Sample Size Re-estimation”

- Folder 12: Peace Article
  ○ “Early Termination of Two Trials of Misoprostol in the Prevention of NSAID-Induced Gastric Ulceration”

- Folder 13: Peace Article

- Folder 14: Peace Articles
  ○ “The Impact of Investigator Heterogeneity in Clinical Trials on Detecting Treatment Differences”
  ○ “Intention to Treat in Clinical Trials”
  ○ “The Importance of Numbers (of Patients) in Clinical Trials”

- Folder 15: Peace Article
  ○ “Introduction” (Drug Information Journal)

- Folder 16: Peace Article
  ○ Meta-Analyses in Ulcer Disease

- Folder 17: Peace Article
  ○ “One-sided or Two-sided p Values: Which Most Appropriately Address the Question of Drug Efficacy?”

- Folder 18: Peace Article
- “Some Comments on the Biopharmaceutical Section and Statistics”
- Folder 19: Peace Article
  - Letter to the Editor: “Some Thoughts on One-tailed Tests”
- Folder 20: Peace Article
  - “TMO: The Trial Management Organization – A New System for Reducing the Time for Clinical Trials”
- Folder 21: Peace Article
  - “To Pool or Not (to Pool)?”
- Folder 22: Peace and Cannon Articles
  - “Biotechnology and the Biostatistician” x 2
  - Biotechnology and the Biostatistician Slides
  - Biotechnology and the Biostatistician Supplements
- Folder 23: Peace and Carter Article
  - “Exposure Analysis of Dichotomous Response Measures in Long-Term Studies”
- Folder 24: Peace and Flora Article
  - “Size and Power Assessments of Tests of Hypotheses on Survival Parameters”
- Folder 25: Peace and Koch Article
  - “Statistical Methods for a Three-period Crossover Design in Which High Dose Cannot be Used First”
- Folder 26: Peace and Schriver Article
  - “P-value and Power Computations in Multiple Look Trials”
- Folder 27: Peace and Schriver Article
  - “Response” (Journal of Clinical Epidemiology)
- Folder 28: Peace and Zimmerman Article
  - “Foreword: Cost-benefit Assessment of Pharmaceutical Products”
- Folder 29: Randolph, Peace, Seaman, Frank, Dickson and Putterman
  - “Bioequivalence of a New 800-MG Cimetidine Tablet with Commercially Available 400-MG Tablets”
- Folder 30: Zimmerman and Peace Article
  - “Cost-effectiveness in Treatment of Peptic Ulcer Disease”
- Folder 31: BASS Programs
- Folder 32: Curriculum Vitae
- Folder 33: Peace Articles
- “Biostatistical Aspects of the Development of H-2 Receptor Antagonist Drugs to Treat Duodenal Disease”
- “Cimetidine Single-dose Active Duodenal Ulcer Trial” 1985
- “A Single Nocturnal Dose of Cimetidine in Active Duodenal Ulcer” 1985
- “Efficacy of a Single Nocturnal Dose of Cimetidine in Active Duodenal Ulcer” 1985
- “Effects of Two Cimetidine Dosage Regimens on Serum Theophylline Levels” 1985
- Folder 34: Peace Article
  - “Biostatistical Aspects of the Development of Anti-anginal Drugs: A Phase II Trial Incorporating an Equiradial Hexagonal Design with RSM”
- Folder 35: Peace Article
  - “The Pooling of Data from Multicentre Clinical Trials”
- Folder 36: Peace Articles
  - “Design Aspects of Cancer Clinical Trial Guidelines for the Clinical Evaluation of Antineoplastic Drugs” 1981
  - “FDA Requirements for Approval of new Drugs”
- Folder 37: Peace Article
  - Non-sequential Analysis of Time to Event Data
- Folder 38: Peace Article
  - Biostatistical Aspects of the Development of Drugs to Treat Alzheimer’s Disease based on ‘Enrichment Designs’”
- Folder 39: Peace Articles
  - Monitoring Adverse Experiences in Clinical Drug Development
  - The Karl E. Peace Lecture Series in Biostatistics
- Folder 40: Overview of the regulation of pharmaceuticals, Part 1
- Folder 41: Overview of the regulation of pharmaceuticals, Part 2
- Folder 42: Overview of the regulation of pharmaceuticals, Part 2 Continued
- Folder 43: Processes of pharmaceutical research and development
- Folder 44: Biostatistical aspects of clinical drug development
- Folder 45: Assessing bioavailability and bioequivalence studies
- Folder 46: Analysis of ratios and decision rules in bioequivalence studies
- Folder 47: Biostatistical aspects of the development of drugs to treat panic disorder
• Folder 48: Biostatistical aspects of the development of drugs for the prevention of NSAID induced gastric ulceration
• Folder 49: George – Anne, April 29, 1960
• Folder 50: 1993 – 2006
• Folder 51: 2007
• Folder 52: 2008
• Folder 53: 2009
• Single Subject Spiral Notebook
  ○ Math 306: Ord. Differential Equations
• Three Subject Spiral Notebook
  ○ Math 453: Adv. Calculus
  ○ Math 506: Cal. Of Finite Differences
  ○ Math 402: Probability

Box 38:

• Folder 1: Articles 1978 – 1987
• Folder 2: Articles 1988 – 1991
• Folder 3: Articles 1992 – 2005
• Folder 4: Articles 2006 – 2007
• Folder 5: Articles 2008 – 2009
• Folder 6: Bibliography of Peace’s Work
• Folder 7: Disc containing other Peace writings

Box 39:

<table>
<thead>
<tr>
<th>Item Number(s)</th>
<th>Title</th>
<th>Description</th>
<th>Image(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Imitating Li, Song</td>
<td>Album leaf in the Manner of Li Sung; Wang Hui* (1632-1717) Ch’ing Dynasty Collection of the National Palace Museum, Republic of China Poster</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Imitating Fan, Zhongli</td>
<td>Album leaf in the manner of Fan K’uan*; Wang Hui (1632-1717) Ch’ing Dynasty Collection of the</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>National Palace Museum, Republic of China Poster</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Imitating Xiao, Zhao</td>
<td>Album leaf in the manner of Hsiao Chao*; Wang Hui (1632-1717) Ch'ing Dynasty Collection of the National Palace Museum, Republic of China Poster</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Imitating Huang He Shan Ren (artistic nickname)</td>
<td>Album leaf in the manner of Fan K’uan*; Wang Hui (1632-1717) Ch'ing Dynasty Collection of the National Palace Museum, Republic of China Poster</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Imitating Da Dian Kuang Ren</td>
<td>Album leaf in the manner of Huang Kung-wang; Wang Hui* (1632-1717) Ch'ing Dynasty Collection of the National Palace Museum, Republic of China Poster</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Anger Management</td>
<td>Written by Zhao, on July 10th, 1984</td>
<td></td>
</tr>
<tr>
<td>Page</td>
<td>Description</td>
<td>Text</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Diligence, truth-seeking, innovation</td>
<td>To my nephew Jian Ping, on October 27th, 1984</td>
<td></td>
</tr>
</tbody>
</table>
| 8    | Cherish the body | Practice makes perfect  
Note to Jian Ping, on December 14th, 1984 |
| 9    | Re-ascending Jinggangshan- to the tune of Shui Diao Ge Tou by Mao, Zedong | I have long aspired to reach for the clouds and I again ascend Jinggangshan.  
Coming from afar to view our old haunt, I find new scenes replacing the old.  
Everywhere orioles sing, swallows dart, streams babble and the roads
<table>
<thead>
<tr>
<th>Page</th>
<th>10</th>
<th>Farewell at Jinmen by Li Bai</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>By Li Bai written by Xu Jianping, third year in high school</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Far, far beyond the Jinmen I am travelling, Reveling in the vast land of Chu state,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Where mountains lull into level fields unfolding, The river finds grandeur through the boundless country.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In its limpid waters a divine moon dives like a flying mirror. Over the towering clouds the sun builds its mirage of day-glory. So far away am I, yet with me still is the homeland water Bearing my boat all the way here.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>11</th>
<th>Soar Bravely</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Written in Nanjing on May 9th, 1984</td>
</tr>
<tr>
<td>#</td>
<td>Title</td>
<td>Text</td>
</tr>
<tr>
<td>----</td>
<td>--------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>12</td>
<td>Qing Ping Yue</td>
<td>Written in March of 1985 in Nanjing Crossing these green hills adds nothing to one’s years. The landscape here is beyond compare.</td>
</tr>
<tr>
<td>13</td>
<td>Seeing a friend</td>
<td>By Li Bai Written by Xu Jianping, third year in high school Green mountains traverse the landscape to the north of town, The river winds around the town east. Here we are bidding farewell, Like a lone dandelion you are on a ten-thousand-mile journey. As a traveler roams like floating clouds, The declining sun set you away. We wave at each other and off you go, There goes a horse separated from its pack, neighing in grief.</td>
</tr>
<tr>
<td>14</td>
<td>In a Bamboo Pavilion by Wang Wei</td>
<td>Sitting alone with bamboo clusters surrounded,</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Author/Artist</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>15</td>
<td>Thatched Cottage and Old Trees</td>
<td>Collection of the National Palace Museum, Republic of China Posters</td>
</tr>
<tr>
<td></td>
<td>and Old Trees by Wen Cheng-Ming</td>
<td>On an intoxicating summer day, the shades of groves interweave one another. A guest comes to help grow new sprouted bamboos, while some pretty swallows fly in a blossom rain. I try to appreciate the prose while refreshing me up by tasting tea. All the traffic outside my home makes a hustle and bustle. But travelers are still wandering in this secular world, wondering where the destination is.</td>
</tr>
<tr>
<td>16</td>
<td>Bamboo and Rocks by Zheng</td>
<td>Zheng Banqiao 1693-1765</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Artist</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>--------</td>
</tr>
<tr>
<td>17</td>
<td>Clearing after the snow on a mountain pass</td>
<td>By T’ang Yin; Ming Dynasty Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td>18</td>
<td>Album leaf in the manner of Hui-ch’ung; Wang Hui (1632-1717) Ch’ing Dynasty</td>
<td>Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td></td>
<td>Title</td>
<td>Artist and Period</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>19</td>
<td>“Countryside in a Clear Summer’s Days” After Chao Ling-jang; Wang Hui Ch’ing Dynasty</td>
<td>Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td>20</td>
<td>Album leaf in the manner of Lu Sung-hien; Wang Hui (1632-1717) Ch’ing Dynasty</td>
<td>Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td>21</td>
<td>Album leaf in the manner of Chao Meng-fu; Wang Hui (1632-1717) Ch’ing Dynasty</td>
<td>Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td>22</td>
<td>“Seven Trees by a River” After Li Ch’eng; Wang</td>
<td>Collection of the National Palace Museum, Republic</td>
</tr>
<tr>
<td></td>
<td>Title</td>
<td>Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>23</td>
<td>Album leaf in the manner of Wang Wei; Wang Hui (1632-1717) Ch‘ing Dynasty</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Album leaf in the manner of Tung Yüan; Wang Hui (1632-1717) Ch‘ing Dynasty</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Album leaf in the manner of Chao Meng-fu; Wang Hui (1632-1717) Ch‘ing Dynasty</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Landscape Wang Hui (1632-1717) Ch‘ing Dynasty</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Museum</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>27</td>
<td>Chatting with a Guest in a Stream-side Pavilion Wen Cheng-Ming, Ming Dynasty</td>
<td>Collection of the National Palace Museum, Republic of China Poster</td>
</tr>
<tr>
<td>28</td>
<td>Mountain Landscape</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>29</td>
<td>Bird on a tree</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>30</td>
<td>Fish</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>31</td>
<td>House on a Hill</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>32</td>
<td>Waterfall and Mountains</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>33</td>
<td>Trees and Mountains</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>34</td>
<td>Trees with Person</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>35</td>
<td>Houses by a Shore</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>36</td>
<td>Flower Tree 1</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>37</td>
<td>Trees and Waterfall</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>38</td>
<td>Trees and a Man</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>39</td>
<td>Islands</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>40</td>
<td>Bamboo Tree</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>41</td>
<td>Flower tree 2</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>42</td>
<td>Mountains, trees, and river</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>43</td>
<td>Flower</td>
<td>Illustrations of</td>
</tr>
<tr>
<td>#</td>
<td>Description</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>----</td>
<td>------------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>44</td>
<td>Tree hanging from cliff</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Boats and Mountains</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>River and cliffs</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>River and cliffs 2</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Cliff and Trees</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Art Work</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>---</td>
<td>----------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>49</td>
<td>Tree</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>50</td>
<td>Tree 2</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>51</td>
<td>Trees and Mountains 2</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>52</td>
<td>Birds on a shore</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>53</td>
<td>Boats by mountains</td>
<td>Illustrations of landscapes Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>No.</td>
<td>Description</td>
<td>Illustrations</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>54</td>
<td>Man sitting by a waterfall</td>
<td>Illustrations of landscapes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jiann-Ping Hsu School Art Work</td>
</tr>
<tr>
<td>55</td>
<td>Time and Place</td>
<td>Illustration of bird and flowers</td>
</tr>
<tr>
<td>56</td>
<td>Water Mountain</td>
<td>Illustration of village below mountain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>School Art Work</td>
</tr>
<tr>
<td>57</td>
<td>Women with emotional expressions</td>
<td>Sketches</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>58</td>
<td>Side view of face</td>
<td>Sketches</td>
</tr>
<tr>
<td>59</td>
<td>Woman side view</td>
<td>Sketches</td>
</tr>
<tr>
<td>60</td>
<td>Philip Gutin</td>
<td>Sketches</td>
</tr>
</tbody>
</table>

Note: Items 10, 11, and 55 are located in Map Drawers B 2 and 3. Also item 60 is located in the Jiann Ping-Hsu Collection Box 4.